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(57) Abstract: The present invention generally
relates to miniature proteins, including miniature
proteins that are permeable to cells. Certain
aspects of the invention are generally related
to miniature proteins, such as avian pancreatic
polypeptide (aPP), modified such that the
miniature proteins are permeable to cells. For
instance, a portion of the aPP, such as the alpha
helix region and/or the type II polyproline
helix region, may be modified to render the
region substantially cationic. As an example,
one or more residues may be substituted with
cationic amino acid residues such as arginine.
The miniature proteins may also have additional
functions, such as the ability to bind to other
proteins such as Bcl2 or hDM2. Another
aspect of the invention is generally directed to
sequences, such as PRR or PPR, that can be added
to other proteins in order to increase their cell
permeability. Still other aspects of the invention
are generally directed to methods of making such
..2 proteins, methods of using such proteins, kits
involving such proteins, and the like.
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FIELD OF INVENTION
The present invention generally relates to miniature proteins, including miniature
proteins that are permeable to cells.
BACKGROUND
Many proteins recognize nucleic acids, other proteins or macromolecular
assemblies using a partially exposed alpha helix. Within the context of a native protein
fold, such alpha helices are usually stabilized by extensive tertiary interactions with
residues that may be distant in primary sequence from both the alpha helix and from each
other. With some exceptions, removal of these tertiary interactions destabilizes the alpha
helix and results in molecules that neither fold nor function in macromolecular
recognition. The ability to recapitulate or perhaps even improve on the recognition
properties of an alpha helix within the context of a small molecule should find utility in
the design of synthetic mimetics or inhibitors of protein function, or new tools for
proteomics research.
Two fundamentally different approaches have been taken to bestow alpha helical
structure on otherwise unstructured peptide sequences. One approach makes use of
modified amino acids or surrogates that favor helix initiation or helix propagation. Some
success has been realized by joining the i and i+7 positions of a peptide with a long-
range disulfide bond to generate molecules whose helical structure was retained at higher
temperatures. A second approach is to pare the extensive tertiary structure surrounding a
given recognition sequence to generate the smallest possible molecule possessing
function. This strategy has generated minimized versions of the Z domain of protein A
(fifty-nine amino acids) and atrial natriuretic peptide (twenty-eight amino acids). The
two minimized proteins, at thirty-three and fifteen amino acids, respectively, displayed
relatively high biological activity. Despite this success, it is difficult to envision a simple
and general application of this truncation strategy in the large number of cases where the
alpha helical epitope is stabilized by residues scattered throughout the primary sequence.
In light of this limitation, a more flexible approach to protein minimization called
protein grafting has been employed. Schematically, protein grafting involves removing
residues required for molecular recognition from their native alpha helical context and
grafting them on the scaffold provided by small yet stable proteins. Numerous
researchers have engineered protein scaffolds to present binding residues on a relatively
small peptide carrier. These scaffolds are small polypeptides onto which residues critical
for binding to a selected target can be grafted. The grafted residues are arranged in
particular positions such that the spatial arrangement of these residues mimics that which
is found in the native protein. These scaffolding systems are commonly referred to as
miniature proteins or miniproteins. A common feature is that the binding residues are
known before the miniprotein is constructed.
Examples of these miniproteins include the thirty-seven amino acid protein
charybdotoxin and the thirty-six amino acid protein, avian pancreatic peptide. Avian
pancreatic polypeptide (aPP) is a polypeptide in which residues fourteen through thirty-
two form an alpha helix stabilized by hydrophobic contacts with an N-terminal type II
polyproline (PPII) helix formed by residues one through eight. Because of its small size
and stability, aPP is a useful scaffold for protein grafting of alpha helical recognition
epitopes.
SUMMARY OF THE INVENTION
The present invention generally relates to miniature proteins, including miniature
proteins that are permeable to cells. The subject matter of the present invention involves,
in some cases, interrelated products, alternative solutions to a particular problem, and/or
a plurality of different uses of one or more systems and/or articles.
Various aspects of the present invention are directed to compositions, including,
in some cases, compositions directed to miniature proteins, for example PYY, aPP, YY2,
YY3, YYl, or the like, which may be modified in various ways, as discussed herein. For
instance, one set of embodiments of the present invention is generally directed to a cell-
permeable miniature protein.
In another set of embodiments, the composition includes a miniature protein
including an alpha helix region, where the miniature protein is modified by substitution
of three to six amino acid residues, inclusively, with arginine residues. The substitutions
may be present at sequential and/or non-sequential positions within the alpha helix
region. In another set of embodiments, the composition includes a miniature protein
including a type II polyproline helix region, where the miniature protein is modified by
substitution of three to six amino acid residues, inclusively, with arginine residues. The
substitutions may be present at sequential and/or non-sequential positions within the type
II polyproline helix region.
The composition, in yet another set of embodiments, includes a PYY including a
type II polyproline helix region. The PYY, in some embodiments, is modified by
substitution of three to six amino acid residues, inclusively, with arginine residues. In
certain cases, the PYY is modified by substitution of at least a portion of the type II
polyproline helix region with the sequence (PPR)n, where n is at least 2.
In one set of embodiments of the present invention, the composition comprises
the sequence APPLPPRNRGEDASPEELSRYYRSLRHYLNLVTRQRY (SEQ ID NO:
50). In another set of embodiments of the present invention, the composition comprises
the sequence APPLPPRNRGEDASPRELSRYYRSLRHYLNLVTRQRY (SEQ ID NO:
51). In yet another set of embodiments of the present invention, the composition
comprises the sequence APPLPPRNRGEDASPRELRRYYRSLRHYLNL VTRQRY
(SEQ ID NO: 52).
According to another set of embodiments, the composition comprises a miniature
protein including a type II polyproline helix region, where the miniature protein is
modified by substitution of at least a portion of the type II polyproline helix region with
the sequence (PPR)n, where n is at least 4. The composition, in yet another set of
embodiments, the composition comprises a miniature protein including a type II
polyproline helix region, where the miniature protein is modified by substitution of at
least a portion of the type II polyproline helix region with the sequence (PRR) n, where n
is at least 3.
In one set of embodiments, the composition includes a miniature protein
modified by substitution of at least three amino acid residues with arginine residues,
where the substitutions are chosen from the group consisting of positions 15, 18, 19, 22,
25, and 26 of the avian pancreatic polypeptide.
In another set of embodiments, the composition is directed to an avian pancreatic
polypeptide (aPP) including an alpha helix region, where the avian pancreatic
polypeptide is modified by substitution of three to six amino acid residues, inclusively,
with arginine residues. The substitutions may be present at sequential and/or non¬
sequential positions within the alpha helix region.
The composition, in accordance with yet another set of embodiments, is directed
to an avian pancreatic polypeptide (aPP) including a type II polyproline helix region,
where the avian pancreatic polypeptide is modified by substitution of three to six amino
acid residues, inclusively, with arginine residues. The substitutions may be present at
sequential and/or non-sequential positions within the type II polyproline helix region.
The composition, according to one set of embodiments, includes an avian
pancreatic polypeptide (aPP) including a type II polyproline helix region, where the
avian pancreatic polypeptide is modified by substitution of at least a portion of the type
II polyproline helix region with the sequence (PPR) n, where n is at least 4. In another set
of embodiments, the composition includes an avian pancreatic polypeptide (aPP)
including a type II polyproline helix region, where the avian pancreatic polypeptide is
modified by substitution of at least a portion of the type II polyproline helix region with
the sequence (PRR)n, where n is at least 3 .
In accordance with yet another set of embodiments, the composition includes an
avian pancreatic polypeptide modified by substitution of at least three amino acid
residues with arginine residues, where the substitutions are chosen from the group
consisting of positions 15, 18, 19, 22, 25, and 26 of the avian pancreatic polypeptide.
In one set of embodiments of the present invention, the composition comprises
the sequence GPSQPTYPGDDAPVRDLRRFYRDLRRYLNVVTRHRY (SEQ ID NO:
21). In another set of embodiments of the present invention, the composition comprises
the sequence GPSQPTYPGDDAPVPJ)LIRFYRDLRRYLNVVTRHRY (SEQ ID NO:
22). In still another set of embodiments of the present invention, the composition
comprises the sequence GPSQPTYPGDDAPVRDLIRFYRDLQRYLNVVTRHRY
(SEQ ID NO: 23).
The composition, in still another set of embodiments, is generally directed to an
avian pancreatic polypeptide (aPP) including an alpha helix region and/or a type II
polyproline helix region that is substantially cationic. In yet another set of embodiments,
the composition includes a miniature protein including an alpha helix region and/or a
type II polyproline helix region that is substantially cationic. In one set of embodiments,
the composition is directed to a cell-permeable avian pancreatic polypeptide.
In another set of embodiments, the composition is directed to a modified avian
pancreatic polypeptide that, when exposed to HeLa cells at a concentration of 1
micromolar, equilibrates inside the HeLa cells at a concentration that is at least 75 times
greater than the equilibration concentration of an unmodified avian pancreatic
polypeptide exposed to the HeLa cells under the same conditions.
The composition, in still another set of embodiments, is directed to a miniature
protein that, when exposed to a population of Jurkat cells at a concentration of 10
micromolar, induces apoptosis in at least about 50% of the Jurkat cells. In accordance
with yet another set of embodiments, the composition includes a modified miniature
protein that, when exposed to HeLa cells at a concentration of 1 micromolar, equilibrates
inside the HeLa cells at a concentration that is at least 75 times greater than the
equilibration concentration of an unmodified miniature protein exposed to the HeLa
cells under the same conditions.
The composition, according to still another set of embodiments of the present
invention, is directed to a protein selected from the group consisting of the following:
GPRRPRRPRRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ ID NO: 24),
GPRRPRRPRRPRRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ ID NO: 25),
GPRRPRRPRRPRRPRRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ ID NO:
26), GPRRPRRPRRPRRPRRPRRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ
ID NO: 27), GPPRPPRPPRPPRGDD APVEDLIRF YNDLQQYLNVVTRHRYC (SEQ
ID NO: 28), GPPRPPRPPRPPRPPRGDD APVEDLIRFYNDLQQYLNVVTRHRYC
(SEQ ID NO: 29), and
GPPRPPRPPRPPRPPRPPRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ ID
NO: 30).
According to one set of embodiments, the composition includes a miniature
protein that is cell permeable and able to bind to Bcl2 with a K of at least about 7 nM.
In another set of embodiments, the composition includes a miniature protein that is cell
permeable and able to bind to hDM2 with a Kd of at least about 10 nM.
In one set of embodiments of the present invention, the composition includes the
sequence GPRRPRRPGRRAPVEDLIRFVGRLLAYFGDTINRYC (SEQ ID NO: 31).
In another set of embodiments of the present invention, the composition includes the
sequence GPRRPRRPGRRAPVVDLIRFRGRWLA YLGDTINRYC (SEQ ID NO: 32).
In yet another set of embodiments of the present invention, the composition includes the
sequence GPRRPRRPGRRAPLGDLISFRGRFLAYFGDTINRYC (SEQ ID NO: 33).
In still another set of embodiments of the present invention, the composition
includes the sequence GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALSLRNYAAAC
(SEQ ID NO: 34). In another set of embodiments of the present invention, the
composition includes the sequence
GPRQPRYPGRDAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ ID NO: 35).
In yet another set of embodiments of the present invention, the composition
includes the sequence GPSRPTRPGDRAPVEDLIRFKFLLQWYLLALSLRNYAAAC
(SEQ ID NO: 36). In still another set of embodiments of the present invention, the
composition includes the sequence
GPRRPRRPGRRAPVEDLIRFKFLLQWFLLALTRHRYAAAC (SEQ ID NO: 37). The
composition, in yet another set of embodiments of the present invention, the composition
includes the sequence GPRRPRRPGRRAPVEDLIRFKFLLQ WYLLALYHNNYAAAC
(SEQ ID NO: 38). The composition, in still another set of embodiments of the present
invention, includes the sequence
GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALSHYNYAAAC (SEQ ID NO: 39).
The composition, in one set of embodiments of the present invention, includes
the sequence G(PRR)nPGRRAPVEDLIRFVGRLLAYFGDTINRYC (SEQ ID NO: 40),
where n is at least 2. The composition, in another set of embodiments of the present
invention, includes the sequence
G(PRR)nPGRRAPVVDLIRFRGRWLAYLGDTINRYC (SEQ ID NO: 41), where n is at
least 2. The composition, in still another set of embodiments of the present invention,
includes the sequence G(PRR)nPGRRAPLGDLISFRGRFLAYFGDTINRYC (SEQ ID
NO: 42), where n is at least 2.
In another set of embodiments of the present invention, the composition includes
the sequence G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ ID
NO: 43), where n is at least 2. The composition, in yet another set of embodiments of
the present invention, includes the sequence
G(PRR)nPGRRAPVEDLIRFKFLLQWFLLALTRHRYAAAC (SEQ ID NO: 44), where
n is at least 2. The composition, in still another set of embodiments, includes the
sequence G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALYHNNYAAAC (SEQ ID NO:
45), where n is at least 2. According to yet another set of embodiments , the composition
includes the sequence G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALSHYNYAAAC
(SEQ ID NO: 46), where n is at least 2.
In one set of embodiments, the composition includes an avian pancreatic
polypeptide (aPP) including a type II polyproline helix region, where the avian
pancreatic polypeptide is modified by substitution of three to six amino acid residues,
inclusively, with arginine residues. The composition, according to another set of
embodiments, includes an avian pancreatic polypeptide (aPP) including a type II
polyproline helix region, where the avian pancreatic polypeptide is modified by
substitution of at least a portion of the type II polyproline helix region with the sequence
(PPR)n, wherein n is at least 2 .
In one set of embodiments of the present invention, the composition includes the
sequence RRPRRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ ID
NO: 47). The composition, in another set of embodiments of the present invention,
includes the sequence RRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC
(SEQ ID NO: 48). In still another set of embodiments of the present invention, the
composition includes the sequence
GPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ ID NO: 49).
In one set of embodiments, the composition comprises a protein modified by the
addition of (PRR)n, wherein n is at least 2, wherein the protein, after modification,
equilibrates inside HeLa cells at a concentration that is at least 75 times greater than the
equilibration concentration of an unmodified protein exposed to the HeLa cells under the
same conditions.
In another set of embodiments, the composition includes a protein modified by
the addition of (PPR)n, wherein n is at least 2, wherein the protein, after modification,
equilibrates inside HeLa cells at a concentration that is at least 75 times greater than the
equilibration concentration of an unmodified protein exposed to the HeLa cells under the
same conditions.
The composition, in yet another set of embodiments, is directed to a protein
containing the sequence (PPR)n, where n is at least 2 . In still another set of
embodiments, the composition includes a protein containing the sequence (PRR)n, where
n is at least 2.
In another aspect, the present invention is directed to a method of making one or
more of the embodiments described herein, for example, a cell permeable miniature
protein. In another aspect, the present invention is directed to a method of using one or
more of the embodiments described herein, for example, a cell permeable miniature
protein.
Other advantages and novel features of the present invention will become
apparent from the following detailed description of various non-limiting embodiments of
the invention when considered in conjunction with the accompanying figures. In cases
where the present specification and a document incorporated by reference include
conflicting and/or inconsistent disclosure, the present specification shall control. If two
or more documents incorporated by reference include conflicting and/or inconsistent
disclosure with respect to each other, then the document having the later effective date
shall control.
BRIEF DESCRIPTION OF THE DRAWINGS
Non-limiting embodiments of the present invention will be described by way of
example with reference to the accompanying figures, which are schematic and are not
intended to be drawn to scale. In the figures, each identical or nearly identical
component illustrated is typically represented by a single numeral. For purposes of
clarity, not every component is labeled in every figure, nor is every component of each
embodiment of the invention shown where illustration is not necessary to allow those of
ordinary skill in the art to understand the invention. In the figures:
Figs. 1A-IB illustrate avian pancreatic polypeptide;
Fig. 2 illustrates an end-on view of part of the alpha helix portion of aPP;
Figs. 3A-3C illustrate the cell permeability of certain cell-penetrating peptides, in
one embodiment of the invention;
Fig. 3D illustrates the CD spectra of the peptides shown in Figs. 3A-3D;
Fig. 4A illustrates the sequences of certain cell permeable miniproteins and
controls, in accordance with one embodiment of the invention;
Figs. 4B, D and E illustrates cell permeability of the same;
Fig. 4C illustrates the CD spectra of molecules shown in Fig 4A
Figs. 5A-5B illustrate cellular viability, in one embodiment of the invention;
Fig. 6 illustrates the temperature dependence of PPII helicity of certain peptides,
according to another embodiment of the invention;
Fig. 7 illustrates the thermostability of RR3-aPP, according to one embodiment of
the invention;
Figs. 8A-8C illustrate various miniature proteins according to certain
embodiments of the invention;
Figs. 9A-9E illustrate time-dependent and temperature and azide-dependent
uptake of certain miniature proteins and controls by HeLa cells, in accordance with one
embodiment of the invention;
Figs. 10A- 1OB illustrate uptake of certain labeled miniature proteins and controls,
in accordance with another embodiment of the invention;
Figs. 1IA-I IB illustrate thermostability of certain miniature proteins in yet
another embodiment of the invention;
Figs. 12A-12C illustrate thermostability of certain miniature proteins in still
another embodiment of the invention;
Fig. 13 illustrates the effect of certain peptides and miniature proteins on cell
viabilities, in one embodiment of the invention; and
Fig. 14 illustrates binding of certain miniature proteins in another embodiment of
the invention.
BRIEF DESCRIPTION OF THE SEQUENCES
SEQ ID NO: 1 is aPP, having the sequence
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY;
SEQ ID NO: 2 is PPBH3-1, having the sequence
GPSQPTYPGDDAPVEDLIRFVGRLLAYFGDTINRY;
SEQ ID NO: 3 is PPBH3-1, having the sequence
GPSQPTYPGDDAPVEDLIRFVGRLLAYFGDTINRYC;
SEQ ID NO: 4 is PPBH3-5, having the sequence
GPSQPTYPGDDAPVVDLIRFRGRWLAYLGDTINRY;
SEQ ID NO: 5 is PPBH3-5, having the sequence
GPSQPTYPGDDAPVVDLIRFRGRWLAYLGDTINRYC;
SEQ ID NO: 6 is PPBH3-6, having the sequence
GPSQPTYPGDDAPLGDLISFRGRFLAYFGDTINRY;
SEQ ID NO: 7 is PPBH3-6, having the sequence
GPSQPTYPGDDAPLGDLISFRGRFLAYFGDTINRYC;
SEQ ID NO: 8 is 1.1, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALTRHRYAAA;
SEQ ID NO: 9 is 1.1, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALTRHRYAAAC;
SEQ ID NO: 10 is 2.1, having the sequence
GKSWMTVPGDDAPVEDLIRFKFLLQWYLLALTRHRYAAA;
SEQ ID NO: 11 is 2.1, having the sequence
GKSWMTVPGDDAPVEDLIRFKFLLQWYLLALTRHRYAAAC;
SEQ ID NO: 12 is (PPR)3-aPP, having the sequence
GPPRPPRPPRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 13 is 3.1, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALYHNNYAAA;
SEQ ID NO: 14 is 3.1, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALYHNNYAAAC;
SEQ ID NO: 15 is 3.2, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALSHYNYAAA;
SEQ ID NO: 16 is 3.2, having the sequence
GPSQPTYPGDDAPVEDLIRPKFLLQWYLLALSHYNYAAAC;
SEQ ID NO: 17 is 3.3, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALSLRNYAAA;
SEQ ID NO: 18 is 3.3, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALSLRNYAAAC;
SEQ ID NO: 19 is 3.4, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALAADAYAAA;
SEQ ID NO: 20 is 3.4, having the sequence
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALAADAYAAAC;
SEQ ID NO: 2 1 is aPP6R1 , having the sequence
GPSQPTYPGDDAPVRDLRRFYRDLRRYLNVVTRHRY;
SEQ ID NO: 22 is aPP5R1 , having the sequence
GPSQPTYPGDDAPVRDLIRFYRDLRRYLNVVTRHRY;
SEQ ID NO: 23 is aPP4R1 , having the sequence
GPSQPTYPGDDAPVRDLIRFYRDLQRYLNVVTRHRY;
SEQ ID NO: 24 is (PRR)3-aPP, having the sequence
GPRRPRRPRRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 25 is (PRR)4-aPP, having the sequence
GPRRPRRPRRPRRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 26 is (PRR)5-aPP, having the sequence
GPRRPRRPRRPRRPRRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 27 is (PRR)6-aPP, having the sequence
GPRRPRRPRRPRRPRRPRRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 28 is (PPR)4-aPP, having the sequence
GPPRPPRPPRPPRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 29 is (PPR)5-aPP, having the sequence
GPPRPPRPPRPPRPPRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 30 is (PPR)6-aPP, having the sequence
GPPRPPRPPRPPRPPRPPRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 3 1 is CP-BcIXL- 1, having the sequence
GPRRPRRPGRRAPVEDLIRFVGRLLAYFGDTINRYC;
SEQ ID NO: 32 is CP-Bcl2-l, having the sequence
GPRRPRRPGRRAPVVDLIRFRGRWLAYLGDTINRYC;
SEQ ID NO: 33 is CP-Bcl2-2, having the sequence
GPRRPRRPGRRAPLGDLISFRGRFLAYFGDTINRYC;
SEQ ID NO: 34 is CP-hDM2-l, having the sequence
GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALSLRNYAAAC;
SEQ ID NO: 35 is CP-hDM2-2, having the sequence
GPRQPRYPGRDAPVEDLIRFKFLLQWYLLALSLRNYAAAC;
SEQ ID NO: 36 is CP-hDM2-3, having the sequence
GPSRPTRPGDRAPVEDLIRFKFLLQWYLLALSLRNYAAAC;
SEQ ID NO: 37 is CP-hDM2-4, having the sequence
GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALTRHRYAAAC;
SEQ ID NO: 38 is CP-hDM2-5, having the sequence
GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALYHNNYAAAC;
SEQ ID NO: 39 is CP-hDM2-6, having the sequence
GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALSHYNYAAAC;
SEQ ID NO: 40 is CP-BcIXL- 1, having the sequence
G(PRR)nPGRRAPVEDLIRFVGRLLAYFGDTINRYC;
SEQ ID NO: 4 1 is CP-Bcl2-l, having the sequence
G(PRR)nPGRRAPVVDLIRFRGRWLAYLGDTINRYC;
SEQ ID NO: 42 is CP-Bcl2-2, having the sequence
G(PRR)nPGRRAPLGDLISFRGRFLAYFGDTINRYC;
SEQ ID NO: 43 is CP-hDM2-l, having the sequence
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALSLRNYAAAC;
SEQ ID NO: 44 is CP-hDM2-4, having the sequence
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALTRHRYAAAC;
SEQ ID NO: 45 is CP-hDM2-5, having the sequence
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALYHNNYAAAC;
SEQ ID NO: 46 is CP-hDM2-6, having the sequence
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALSHYNYAAAC;
SEQ ID NO: 47 is RR5-aPP, having the sequence
RRPRRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 48 is RR4-aPP, having the sequence
RRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 49 is RR3-aPP, having the sequence
GPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 50 is YY23R1 , having the sequence
APPLPPRNRGEDASPEELSRYYRSLRHYLNLVTRQRY;
SEQ ID NO: 5 1 is YY24R1 , having the sequence
APPLPPRNRGEDASPRELSRYYRSLRHYLNLVTRQRY;
SEQ ID NO: 52 is YY25R1 , having the sequence
APPLPPRNRGEDASPRELRRYYRSLRHYLNLVTRQRY;
SEQ ID NO: 53 is PYY, having the sequence
YPAKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY;
SEQ ID NO: 54 is GPSQPTYPGDDAPVRDLRRFYRDLQQYLNVVTRHRY;
SEQ ID NO: 55 is GPSQPTYPGDDAPVRDLRRFYNDLRQYLNVVTRHRY;
SEQ ID NO: 56 is GPSQPTYPGDDAPVRDLRRFYNDLQRYLNVVTRHRY;
SEQ ID NO: 57 is GPSQPTYPGDDAPVRDLIRFYRDLRQYLNVVTRHRY;
SEQ ID NO: 58 is GPSQPTYPGDDAPVRDLIRFYNDLRRYLNVVTRHRY;
SEQ ID NO: 59 is GPSQPTYPGDDAPVEDLRRFYRDLRQYLNVVTRHRY;
SEQ ID NO: 60 is GPSQPTYPGDDAPVEDLRRFYRDLQRYLNVVTRHRY;
SEQ ID NO: 6 1 is GPSQPTYPGDDAPVEDLRRFYNDLRRYLNVVTRHRY;
SEQ ID NO: 62 is GPSQPTYPGDDAPVEDLIRFYRDLRRYLNVVTRHRY;
SEQ ID NO: 63 is GPSQPTYPGDDAPVRDLRRFYRDLRQYLNVVTRHRY;
SEQ ID NO: 64 is GPSQPTYPGDDAPVRDLRRFYRDLQRYLNVVTRHRY;
SEQ ID NO: 65 is GPSQPTYPGDDAPVRDLRRFYNDLRRYLNVVTRHRY;
SEQ ID NO: 66 is GPSQPTYPGDDAPVEDLRRFYRDLRRYLNVVTRHRY;
SEQ ID NO: 67 is YY2, having the sequence
APPLPPRNRGEDASPEELSRYYASLRHYLNLVTRQRY;
SEQ ID NO: 68 is (PRR)3, having the sequence PRRPRRPRR;
SEQ ID NO: 69 is (PRR)4, having the sequence PRRPRRPRRPRR;
SEQ ID NO: 70 is (PRR) 5, having the sequence PRRPRRPRRPRRPRR;
SEQ ID NO: 7 1 is (PRR)6, having the sequence PRRPRRPRRPRRPRRPRR;
SEQ ID NO: 72 is R8, having the sequence RRRRRRRR;
SEQ ID NO: 73 is R 12 , having the sequence RRRRRRRRRR;
SEQ ID NO: 74 is R 10, having the sequence RRRRRRRRRRRR;
SEQ ID NO: 75 is R
15
, having the sequence RRRRRRRRRRRRRRR;
SEQ ID NO: 76 is SAP or Flu-SAP, having the sequence FIu-
VRLPPPVRLPPPVRLPPP;
SEQ ID NO: 77 is Bac or Flu-Bac, having the sequence Flu-GPRPLPFPRPG;
SEQ ID NO: 78 is Tat or Flu-Tat, having the sequence Flu-GRKKRRQRRRPPQ;
SEQ ID NO: 79 is FIu-R8, having the sequence Flu-GRRRRRRRR;
SEQ ID NO: 80 is FIu-Ri0, having the sequence Flu-GRRRRRRRRRR;
SEQ ID NO: 81 is FIu-R 12 , having the sequence Flu-GRRRRRRRRRRRR;
SEQ ID NO: 82 is FIu-PPR3, having the sequence Flu-GPPRPPRPPR;
SEQ ID NO: 83 is FIu-PPR4, having the sequence Flu-GPPRPPRPPRPPR;
SEQ ID NO: 84 is FIu-PPR6, having the sequence FIu-
GPPRPPRPPRPPRPPRPPR;
SEQ ID NO: 85 is FIu-PRR3 or FIu-(PRR)3, having the sequence FIu-
GPRRPRRPRR;
SEQ ID NO: 86 is FIu-PRR4 or FIu-(PRR)4, having the sequence FIu-
GPRRPRRPRRPRR;
SEQ ID NO: 87 is FIu-PRR5 or FIu-(PRR)5, having the sequence FIu-
GPRRPRRPRRPRRPRR;
SEQ ID NO: 88 is FIu-PRR6 or FIu-(PRR)6, having the sequence FIu-
GPRRPRRPRRPRRPRRPRR;
SEQ ID NO: 89 is aPP-Flu, having the sequence
GPSQPTYPGDDAPVEDLIRF YNDLQQYLNVVTRHRYC-FIU;
SEQ ID NO: 90 is RR3-aPP-Flu, having the sequence
GPRRPRRPGRRAPVEDLIRF YNDLQQYLNVVTRHRYC-FIU;
SEQ ID NO: 9 1 is RR^aPP-FIu, having the sequence
RRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC-FIU;
SEQ ID NO: 92 is RR5-aPP-Flu, having the sequence
RRPRRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC-FIU;
SEQ ID NO: 93 is PPR3Y or (PPR)3Y, having the sequence PPRPPRPPRY;
SEQ ID NO: 94 is PPR4Y or (PPR)4Y, having the sequence PPRPPRPPRPPRY;
SEQ ID NO: 95 is PPR5Y or (PPR)5Y, having the sequence
PPRPPRPPRPPRPPRY;
SEQ ID NO: 96 is PPR Y or (PPR)6Y, having the sequence
PPRPPRPPRPPRPPRPPRY;
SEQ ID NO: 97 is PRR3Y or (PRR)3Y, having the sequence PRRPRRPRRY;
SEQ ID NO: 98 is PRR4Y or (PRR)4Y, having the sequence
PRRPRRPRRPRRY;
SEQ ID NO: 99 is PRR5Y or (PRR)5Y, having the sequence
PRRPRRPRRPRRPRRY;
SEQ ID NO: 100 is PRR6Y or (PRR)6Y, having the sequence
PRRPRRPRRPRRPRRPRRY;
SEQ ID NO: 101 is aPP-Ac, having the sequence
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRYC-Ac;
SEQ ID NO: 102 is RR3-aPP-Ac, having the sequence
GPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC-Ac;
SEQ ID NO: 103 is RR^aPP-Ac, having the sequence
RRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC-Ac;
SEQ ID NO: 104 is RR5-aPP-Ac, having the sequence
RRPRRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYCAc;
SEQ ID NO: 105 is aPP4R1 -Flu, having the sequence
GPSQPTYPGDDAPVRDLIRFYRDLQRYLNVVTRHR Y-FIu;
SEQ ID NO: 106 is aPP5RI -Flu, having the sequence
GPSQPTYPGDDAPVRDLIRFYRDLRRYLNVVTRHRY-FIU;
SEQ ID NO: 107 is aPP6R1 -Flu, having the sequence
GPSQPTYPGDDAPVRDLRRFYRDLRRYLNVVTRHRY-Flu;
SEQ ID NO: 108 is YY2-Flu, having the sequence
APPLPPRNRGEDASPEELSRYYASLRH YLNLVTRQRY-FIu;
SEQ ID NO: 109 is YY23R1 -Flu, having the sequence
APPLPPRNRGEDASPEELSRYYRSLRHYLNLVTRQRY-Flu;
SEQ ID NO: 110 is YY24R1 -Flu, having the sequence
APPLPPRNRGEDASPRELSRYYRSLRHYLNL VTRQRY-FIu;
SEQ ID NO: 111 is YY25R1-Flu, having the sequence
APPLPPRNRGEDASPRELRRYYRSLRHYLNL VTRQRY-FIu;
SEQ ID NO: 112 is R8Y-FIu, having the sequence RRRRRRRRY-Flu;
SEQ ID NO: 113 is Tat (48-6O)-FIu, having the sequence
GRKKRRQRRRPPQY-Flu;
SEQ ID NO: 114 is Penetratin-Flu, having the sequence
RQIKIWFQNRRMKWKK-Flu;
SEQ ID NO: 115 is Transportan-Flu, having the sequence
GWTLNSAGYLLKINLKALAALAKKIL-Flu;
SEQ ID NO: 116 is KLA-FIu, having the sequence
KLALKLALKALKAALKLA-Flu;
SEQ ID NO: 117 is R8Y, having the sequence RRRRRRRRY;
SEQ ID NO: 118 is Tat (48-60), having the sequence GRKKRRQRRRPPQY;
SEQ ID NO: 119 is Penetratin, having the sequence RQIKIWFQNRRMKWKK;
SEQ ID NO: 120 is Transportan, having the sequence
GWTLNSAGYLLKINLKALAALAKKIL;
SEQ ID NO: 121 is KLA, having the sequence KLALKLALKALK AALKLA;
SEQ ID NO: 122 is aPP, having the sequence
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRYC;
SEQ ID NO: 123 is YYl, having the sequence
APPLPPRNPGEDASPEELSRYYASLRHYLNLVTRQRY;
SEQ ID NO: 124 is YY3, having the sequence
APPLPPRNRPGEDASPEELSRYYASLRHYLNLVTRQRY.
DETAILED DESCRIPTION
The present invention generally relates to miniature proteins, including miniature
proteins that are permeable to cells. Certain aspects of the invention are generally related
to miniature proteins, such as avian pancreatic polypeptide (aPP), modified such that the
miniature proteins are permeable to cells. For instance, a portion of the aPP, such as the
alpha helix region and/or the type II polyproline helix region, may be modified to render
the region substantially cationic. As an example, one or more residues may be
substituted with cationic amino acid residues such as arginine. The miniature proteins
may also have additional functions, such as the ability to bind to other proteins such as
Bcl2 or hDM2. Another aspect of the invention is generally directed to sequences, such
as PRR or PPR, that can be added to other proteins in order to increase their cell
permeability. Still other aspects of the invention are generally directed to methods of
making such proteins, methods of using such proteins, kits involving such proteins, and
the like.
Various aspects of the invention are generally directed to various miniature
proteins, such as aPP or PYY (modified pancreatic peptide YY), that has been modified
such that the miniature proteins are permeable to cells. For example, the miniature
proteins may be modified at one or more regions in a manner that causes the regions to
become substantially cationic. One or more residues on a miniature protein may be
substituted with, for example, cationic amino acid residues. Non-limiting examples of
cationic amino acid residues include arginine or histidine. As used herein, the terms
"miniature protein" or "miniprotein" refer to a relatively small protein containing at least
a protein scaffold and one or more additional domains or regions that help to stabilize its
tertiary structure. In some cases, the miniature protein may have a length of no more
than 40 or 45 residues. For instance, in various embodiments, the miniature protein may
have a length of 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 residues.
In some cases, a modified miniature protein may be identified as one that is cell
permeable by exposing a cell, such as a HeLa cell, to a modified miniature protein and
comparing the concentration of the modified miniature protein within the cell after
equilibration (e.g., when a steady-state concentration is reached) to the concentration of
an unmodified miniature protein exposed to the cell under the same conditions. A cell
permeable miniature protein or other peptide has a greater ability to enter the cell, e.g., it
can enter the cell at a greater concentration than an unmodified protein under the same
conditions. In some cases the concentration of the modified miniature protein within the
cell is greater than outside of the cell at equilibrium, for example, at least about 50 times
greater than the concentration of the unmodified miniature protein. In some cases, the
cell permeable miniature protein may reach higher concentrations, e.g., at least about 75,
at least about 100, at least about 300, etc., times greater than the concentration of the
unmodified miniature protein.
For example, for a modified aPP as used herein, cells such as a HeLa cells may
be exposed to a concentration of 1 micromolar of miniature protein (modified and
unmodified), and the concentrations of each within the cell may be determined in some
fashion. As a specific example, the miniature proteins may be labeled with a fluorescent
entity, such as fluorescein, and their relative concentrations determined using techniques
such as flow cytometry, using routine techniques known to those of ordinary skill in the
art. A non-limiting example of a flow cytometry technique is FACS (fluorescence-
activated cell sorting).
The term "protein," as used herein, is given its ordinary definition in the art, e.g.,
any of a group of complex organic compounds which contain carbon, hydrogen, oxygen,
nitrogen and usually sulfur, which are widely distributed in plants and animals. Twenty
different amino acids are commonly found in proteins and each protein has a unique,
genetically defined amino acid sequence which determines its specific shape and
function. The term "protein" is generally used herein interchangeably with the terms
"peptide" and "polypeptide." The term "protein scaffold" refers to a region or domain of
a relatively small protein, such as a miniature protein, that has a conserved tertiary
structural motif which can be modified to display one or more specific amino acid
residues in a fixed conformation.
Non-limiting examples of miniature proteins include the PP fold protein
scaffolds, which generally contain thirty-six amino acids and are the smallest known
globular proteins. Despite their small size, PP fold proteins are stable and remain folded
under physiological conditions. Some PP fold protein scaffolds of the invention
comprise two anti-parallel helices, an N-terminal type II polyproline helix (PPII)
between amino acid residues two and eight and an alpha helix between residues 14 and
3 1 and/or 32. The stability of the PP fold protein scaffolds of the invention derives
predominantly from interactions between hydrophobic residues on the interior face of the
alpha helix at positions 17, 20, 24, 27, 28, 30, and 3 1 and the residues on the two edges
of the polyproline helix at positions 2, 4, 5, 7, and 8.
Positions for grafting these binding site residues on the protein scaffold include,
but are not limited to, positions on the solvent-exposed alpha-helical face of aPP.
Substitutions of binding site residues may be made, in some cases, for residues involved
in stabilizing the tertiary structure of the miniature protein. As used herein, the term
"exposed on the alpha helix domain" means that an amino acid substituted, for example,
into aPP or PYY, is available for association or interaction with another molecule and is
not otherwise bound to or associated with another amino acid residue on the aPP or
PYY. This term is used interchangeably with the term "solvent-exposed alpha helical
face" and similar terms (e.g., "solvent-exposed face of the aPP alpha helix").
Members of the PP fold family of protein scaffolds which are contemplated for
use in the present invention include, but are not limited to, avian pancreatic polypeptide
(aPP), Neuropeptide Y, lower intestinal hormone polypeptide and pancreatic peptide YY
(PYY) (e.g., SEQ ID NO: 53). In one embodiment, the protein scaffold comprises the
PP fold protein, avian pancreatic polypeptide (SEQ ID NO: 1 or 122). aPP is a PP fold
polypeptide characterized by a short (eight residue) amino-terminal type II polyproline
helix linked through a type I beta turn to an eighteen residue alpha helix. Because of its
small size and stability, aPP is an excellent protein scaffold for, e.g., protein grafting of
alpha-helical recognition epitopes.
It should be noted that the natural sequence of aPP is as shown in SEQ ID NO: 1,
i.e., GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY. However, in some
cases, the aPP may be modified by the addition of a terminal C, as is shown in SEQ ID
NO: 122, i.e., GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRYC. The C may
be added to the end of aPP to facilicate the binding of other species to aPP, for example,
a reporter species such as fluorescein, as is shown in SEQ ID NO: 89 for aPP-Flu.
Similarly, any other miniature protein or peptide discussed herein may be modified by
the addition of a terminal C or a terminal Y (if one is not already present), e.g., to
facilitate binding, for example, PPBH3-1 (see SEQ ID NOs 2 and 3), (PRR)3-aPP (SEQ
ID NO: 24), CP-BclXL-1 (SEQ ID NO: 31), CP-hDM2-l (SEQ ID NO: 34), etc.
One aspect of the invention is generally directed to miniature proteins, such as
avian pancreatic polypeptide (aPP), that include an alpha helix region and/or a type II
polyproline helix region that is modified by the substitution and/or addition of various
amino acid residues with cationic amino acid residues such as arginine or histidine. The
modified aPP may also include other substitutions, e.g., for improving binding
properties, such as is discussed below. Referring now to Fig. IA, the structure of avian
pancreatic polypeptide (aPP) (SEQ ID NO: 1) is shown, including a type II polyproline
helix region ("PPII helix"), a beta turn, and an alpha-helix region. Fig. IB illustrates the
structure of the aPP when it is properly folded. However, it should be understood that
the miniature proteins discussed herein are not limited to aPP (SEQ ID NO: 1), but
include other suitable miniature proteins. A non-limiting example includes PYY (SEQ
ID NO: 53).
Without wishing to bound by any theory, it is believed that the substitutions may
chosen to cause the alpha helix region and/or type II polyproline helix region to become
substantially cationic, i.e., such that the alpha helix region and/or the type II polyproline
helix region exhibits a net positive charge in a buffered aqueous solution having neutral
pH, such as phosphate-buffered saline. In some cases, the substitutions may chosen to
cause only a portion of the alpha helix region and/or type II polyproline helix region to
become substantially cationic, and it is believed that such substitutions may cause the
miniature protein to become relatively cell permeable. Such cationic properties can be
determined, for instance, by using charge electrophoresis or isoelectric focusing to
determine the charge of the protein (or portions of the protein) under various conditions.
Any number of residues within the alpha helix region and/or the type II
polyproline helix region may be substituted with arginine residues or the like, for
instance, at least two residues, at least three residues, at least four residues, etc. In some
cases, there may be between 3 and 6 or between 3 and 5 residues (inclusively) that are
substituted with a cationic amino acid residue. The substitutions may be present on any
location within the alpha helix region and/or the type II polyproline helix region, and
may be consecutive or non-consecutive, in some cases. In some embodiments, the
cationic amino acid residue substitutions are located in only one region of the miniature
protein, e.g., within only the alpha helix region or within only the type II polyproline
helix region (of course, in some cases, there may be other types of substitutions
elsewhere, e.g., for altering binding properties of the molecule).
Thus, one set of embodiments is directed to a miniature protein, such as aPP, that
includes a type II polyproline helix region modified by the substitution and/or addition of
various amino acid residues with cationic amino acid residues, and optionally with other
substitutions as well. The residues chosen for substitution may be present anywhere
within the type II polyproline helix region, and may be independently consecutive or
non-consecutive.
In some cases, the residues chosen for substitution are chosen such that the type
II polyproline helix is enriched in proline and/or arginine residues. For instance, residues
may be substituted (and/or new residues may be added to the type II polyproline helix)
such that one or more proline and/or arginine residues are located next to each other, and
in some cases, such that one or more repeat units of PPR and/or PRR are present within
the type II polyproline helix. For instance, in one set of embodiments, the type II
polyproline helix may include at least one portion having a sequence PPR and/or PRR,
and in some cases, the type II polyproline helix may include more than one PPR and/or
PRR sequence, e.g., (PPR)n and/or (PRR)n, where n is at least 3, e.g., 3, 4, 5, 6, etc. In
certain cases, the type II polyproline helix may contain other residues as well, and in
some cases, the residues may be located between or even within PPR and/or PRR repeat
units within the type II polyproline helix. Specific, non-limiting examples of such
sequences include SEQ ID NO: 47 is RR5-aPP (SEQ ID NO: 47), SEQ ID NO: 48 is
RR4-aPP (SEQ ID NO: 48), or SEQ ID NO: 49 is RR3-aPP (SEQ ID NO: 49), which
each contain varying numbers of the PRR repeat unit within the type II polyproline helix
of the miniature protein. Other non-limiting examples include SEQ ID NOs: 12 and 24-
30. It should also be noted, as discussed below, that PPR and/or PRR repeat units may
be added to any suitable protein in order to increase its cell permeability.
Still other non-limiting examples include the modification of avian pancreatic
polypeptide able to bind to (or otherwise interact with) other proteins such as Bcl2 or
hDM2. It should be noted that such binding may be specific or non-specific, and involve
various noncovalent interactions such as including hydrogen bonding, metal
coordination, hydrophobic forces, van der Waals forces, pi-pi interactions, and/or
electrostatic effects. For instance, miniature proteins such as PPBH3-1 (e.g., SEQ ID
NO: 2), PPBH3-5 (e.g., SEQ ID NO: 4), or PPBH3-6 (e.g., SEQ ID NO: 6), 1.1 (e.g.,
SEQ ID NO: 9), 2 .1 (SEQ ID NO: 11), 3.1 (SEQ ID NO: 14), 3.2 (SEQ ID NO: 16), 3.3
(SEQ ID NO: 18), 3.4 (SEQ ID NO: 20), etc. can be modified to include any number of
PPR and/or PRR sequences, e.g., as shown in the sequences
G(PRR)nPGRRAPVEDLIRFVGRLLAYFGDTrNRYC (SEQ IDNO: 40),
G(PRR)nPGRRAPVVDLIRFRGRWLAYLGDTINRYC (SEQ ID NO: 41),
G(PRR) nPGRRAPLGDLISFRGRFLAYFGDTINRYC (SEQ ID NO: 42) for various
Bel-binding miniature proteins, or
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ ID NO: 43),
G(PRR) nPGRRAPVEDLIRFKFLLQWFLLALTRHRYAAAC (SEQ ID NO: 44),
G(PRR) nPGRRAPVEDLIRFKFLLQWYLLALYHNNYAAAC (SEQ ID NO: 45), or
G(PRR) nPGRRAPVEDLIRFKFLLQWYLLALSHYNYAAAC (SEQ ID NO: 46) for
various hDM2-binding miniature proteins, where n is any positive integer, e.g., as
previously described. In addition, it should be noted that such modifications are not
limited to avian pancreatic polypeptides, but include other miniature proteins such as
PYY (SEQ ID NO: 53), YY2 (SEQ ID NO: 67), YYl (SEQ ID NO: 123), or YY3 (SEQ
ID NO: 124). For instance, YY2 may be modified by using one or more PPR groups,
e.g., as in YY23R1 (SEQ ID NO: 50), YY24R1 (SEQ ID NO: 51), or YY2 5R1 (SEQ ID NO:
52 ) .
Thus, in one set of embodiments, the avian pancreatic polypeptide may be
selected to be able to bind to Bcl2, and the avian pancreatic polypeptide may be modified
as discussed above in order to increase its cell permeability. For example, the avian
pancreatic polypeptide may include an alpha helix and/or a type II polyproline helix
region modified by the substitution and/or addition of various amino acid residues with
cationic amino acid residues. After such substitutions, the avian pancreatic polypeptide
may still exhibit Bcl2 binding activity, e.g., with a Kd of at least about 7 nM, at least
about 10 nM, at least about 20 nM, at least about 30 nM, at least about 50 nM, at least
about 100 nM, etc. K< may be measured using any suitable technique known to those of
ordinary skill in the art. A non-limiting example are fluorescence polarization analysis
techniques such as those discussed in A.C. Gemperli, et al, "Paralog-selective Ligands
for Bcl-2 Proteins," J . Am. Chem. Soc, 2005, 127, 1596-1597, or in J .W. Chin, et al,
"Design and Evolution of a Miniature Bcl-2 Binding Protein," Angew. Chem. Int. Ed.
Eng., 2001, 40, 3806-3809. Non-limiting examples of such sequences include CP-
BclXL-1 (SEQ ID NO: 31), CP-Bcl2-l (SEQ ID NO: 32), or CP-Bcl2-2 (SEQ ID NO:
33). See also Fig. 14. Additional examples include sequences that include one or more
repeat units of PPR and/or PRR are present within the type II polyproline helix, for
instance, (PPR)n and/or (PRR)n, where n is at least 3, e.g., 3, 4, 5, 6, etc., e.g., as
previously discussed. Specific non-limiting example include
G(PRR)nPGRRAPVEDLIRFVGRLLAYFGDTINRYC (SEQ ID NO: 40),
G(PRR)nPGRRAPVVDLIRFRGRWLAYLGDTINRYC (SEQ ID NO: 41), or
G(PRR)nPGRRAPLGDLISFRGRFLAYFGDTINRYC (SEQ ID NO: 42).
As another example, in another set of embodiments, the avian pancreatic
polypeptide is selected to be able to bind to hDM2, and the avian pancreatic polypeptide
can be modified to increase its permeability into cells. As discussed above, the avian
pancreatic polypeptide can include an alpha helix and/or a type II polyproline helix
region modified by the substitution and/or addition of various amino acid residues with
cationic amino acid residues, and after such substitutions, the avian pancreatic
polypeptide may still exhibit hDM2 binding activity, e.g., with a Kd at least about 10 nM,
at least about 20 nM, at least about 30 nM, at least about 50 nM, at least about 100 nM,
at least about 300 nM, etc. Specific examples include, but are not limited to, sequences
having one or more repeat units of PPR and/or PRR are present within the type II
polyproline helix, for instance, (PPR)n and/or (PRR)n. where n is at least 3. e.g., 3, 4, 5.
6, etc., e.g., as discussed above. Examples of these include CP-liDM2-l (SEQ ID NO:
34), CP-hDM2-2 (SEQ ID NO: 35), CP-hDM2-3 (SEQ ID NO: 36), CP-hDM2-4 (SEQ
ID NO: 37), CP-hDM2-5 (SEQ ID NO: 38), or CP-hDM2-6 (SEQ ID NO: 39). Other
examples include, but are not limited to,
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ ID NO: 43),
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALTRHRYAAAC (SEQ ID NO: 44),
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALYHNNYAAAC (SEQ ID NO: 45), or
G(PRR)nPGRRAPVEDLIRFKFLLQ WYLLALSHYNYAAAC (SEQ ID NO: 46), where
n is at least 3, e.g., 3, 4, 5, 6, etc.
In some cases, the modified avian pancreatic polypeptide may be able to
permeate cells such as Jurkat cells due to the modifications such that, when the modified
avian pancreatic polypeptide is exposed to a population of Jurkat cells, the modified
avian pancreatic polypeptide is able to induce apoptosis (programmed cell death) in at
least about 50% of the Jurkat cells at some concentration, such as about 10 micromolar.
For instance, the modified avian pancreatic polypeptide may be selected to be able to
bind to or otherwise interact with Bcl2 and/or hDM2, as discussed above.
Another set of embodiments is directed to a miniature protein, such as aPP, that
includes an alpha helix region modified by the substitution and/or addition of various
amino acid residues with cationic amino acid residues. A non-limiting example of a
cationic amino acid residue is arginine. The residues chosen for substitution may be
present anywhere within the alpha helix region, and may be independently consecutive
or non-consecutive.
In one embodiment, the residues chosen for substitution may be ones that are
located on one portion or side of the alpha helix. For instance, referring now to Fig. 2,
from an end-on view of the alpha helix portion of aPP (starting from A at residue 12,
indicated by arrow 51, and moving clockwise), the residues to be substituted may be
chosen from the ones located on one side of the alpha helix, e.g., on an exterior side or a
solvent-exposed face of the alpha helix when the protein is properly folded, as indicated
by portions 54. Without wishing to be bound by any theory, it is believed that such
substitutions can cause the exterior side of the miniature protein to appear positively
charged or cationic, which may facilitate permeation of the miniature protein into cells.
Thus, for example, in aPP, the residues chosen for substitution may be selected from
positions 12, 15, 18, 19, 22, 25, and/or 26. Non-limiting examples of such substitutions
include aPP4R1 (SEQ ID NO: 21), aPP5R1 (SEQ ID NO: 22), aPP6R1 (SEQ ID NO: 23), as
well as SEQ ID NOs: 54-66.
In some aspects, the modified miniature proteins are able to associate with (or
bind to) specific sequences of DNA or other proteins. These miniature proteins may be
able to bind, for example, to DNA or other proteins with high affinity and selectivity. As
used herein, the term "bind" or "binding" refers to the specific association or other
specific interaction between two molecular species, such as, but not limited to, protein-
DNA interactions and protein-protein interactions, for example, the specific association
between proteins and their DNA targets, receptors and their ligands, enzymes and their
substrates, etc. Such binding may be specific or non-specific, and can involve various
noncovalent interactions such as including hydrogen bonding, metal coordination,
hydrophobic forces, van der Waals forces, pi-pi interactions, and/or electrostatic effects.
It is contemplated that such association may be mediated through specific sites on each
of two (or more) interacting molecular species. Binding can be mediated by structural
and/or energetic components. In some cases, the latter will comprise the interaction of
molecules with opposite charges.
In one set of embodiments, the invention involves a technique known as protein
grafting. Protein grafting has generally been described in U.S. Patent Application Serial
No. 09/840,085, filed April 24, 2001, entitled "Modified Avian Pancreatic Polypeptide
Miniature Binding Proteins," by A.S. Shrader, et al, now U.S. Patent No. 7,297,762,
issued November 20, 2007, incorporated herein by reference. Briefly, protein grafting
identifies binding site residues from a globular protein that is able to participate in
binding-type associations between that protein and its specific binding partners, then the
residues are grafted onto a small but stable protein scaffold. As used herein, the term
"binding site" refers to the reactive region or domain of a molecule that directly
participate in its specific binding with another molecule. For example, when referring to
the binding site on a protein or nucleic acid, binding occurs as a result of the presence of
specific amino acids or nucleotide sequence, respectively, that interact with the other
molecule. Examples of protein scaffolds of the invention comprise members of the
pancreatic fold (PP fold) protein family, particularly avian pancreatic polypeptide (aPP)
or pancreatic peptide YY (PYY).
Thus, in one aspect, a modified miniature protein may be able to associate with or
bind to a specific sequence of DNA. In some embodiments, the DNA sequence may
comprise sites for known proteins that bind to that specific DNA sequence (contemplated
known proteins would be, e.g., a promotor or regulator). For example, in the design of a
DNA-binding miniature protein, the amino acid residues of a known protein that
participate in binding or other association of the protein to that particular DNA sequence
are identified.
In some embodiments of the present invention, the relevant binding residues are
identified using three-dimensional models of a protein or protein complex based on
crystallographic studies while in other embodiments they are identified by studies of
deletion or substitution mutants of the protein. The residues that participate in binding of
the protein to the specific DNA sequence are then grafted onto those positions of the
miniature protein that are not necessary to maintain the tertiary structure of the protein
scaffold to form the DNA-binding miniature protein. The identification of such positions
can readily be determined empirically by persons of ordinary skill in the art. Other
embodiments of the present invention involve the screening of a library of modified
miniproteins that contain peptide species capable of specific association or binding to
that specific DNA (or, in other cases, protein) sequence or motif.
Generally, it is contemplated that any potential binding site on a DNA sequence
can be targeted using the DNA binding miniature proteins of the invention. Certain
embodiments include miniature proteins having helical structures which bind to a DNA
binding site. In some embodiments, the binding involves a basic region leucine zipper
(bZIP) structure, while in other embodiments the structure involves a basic-helix-loop-
helix (bHLH) structure. In another embodiment, the binding involves a structure like
those found in homeodomain proteins. Example bZIP structures include, but are not
limited to, those found in GCN4 and C/EBP-delta, and example bHLH structures
include, but are not limited to, those found in Max, Myc and MyoD. Example
homeodomain structures include, but are not limited to, those found in the Q50 engrailed
variant protein.
As mentioned, one aspect of the present invention is generally directed to the
addition of certain sequences containing repeat units such as PRR and/or PPR that may
be added to any suitable protein in order to increase its cell permeability. Without
wishing to be bound by any theory, it is believed that the presence of (PRR)n and/or
(PPR)n repeat units (where n is at least 2, e.g., 2, 3, 4, 5, 6, 7, 8, etc.) may cause the
formation of a helical structure within the modified protein, such as a type II polyproline
helical structure, that appears to be positively charged or cationic (or at least substantially
cationic), which may facilitate permeation of the protein into cells. Thus, a protein may
be modified by adding a plurality of repeat units such as PRR and/or PPR at any suitable
location, e.g., at a terminal end of the protein, within an internal sequence of the protein,
or the like. In some cases, the modification may be chosen such that the repeat units are
positioned on an exterior surface of the protein.
The cell permeability of the protein may be determined, for example, as
previously described. Thus, for example, cells such as a HeLa cells, Jurkat cells, etc.,
may be exposed to a concentration of 1 micromolar of modified protein, and the
concentrations of each within the cell may be determined in some fashion. For example,
the protein may be labeled with a fluorescent entity, such as fluorescein, and the relative
concentrations determined using techniques such as flow cytometry.In some aspects, a
miniature protein of the present invention is produced and selected using a phage display
method. In such a method, display of recombinant miniature proteins on the surface of
viruses which infect bacteria (bacteriophage or phage) make it possible to produce
soluble, recombinant miniature proteins having a wide range of affinities and kinetic
characteristics. To display the miniature proteins on the surface of phage, a synthetic
gene encoding the miniature protein is inserted into the gene encoding a phage surface
protein (pill) and the recombinant fusion protein is expressed on the phage surface.
Variability may be introduced into the phage display library to select for miniature
proteins which not only maintain their tertiary, helical structure but which also display
increased affinity for a preselected target because the critical (or contributing but not
critical) binding residues are optimally positioned on the helical structure.
Since the recombinant proteins on the surface of the phage are functional, phage
bearing miniature proteins that bind with high-affinity to a particular target DNA or
protein can be separated from non-binding or lower affinity phage by using techniques
such as antigen affinity chromatography. Mixtures of phage are allowed to bind to the
affinity matrix, non-binding or lower affinity phage are removed by washing, and bound
phage are eluted by treatment with acid or alkali. Depending on the affinity of the
miniature protein for its target, enrichment factors of twenty-fold to a million-fold are
obtained by a single round of affinity selection. By infecting bacteria with the eluted
phage, however, more phage can be grown and subjected to another round of selection.
In this way, an enrichment of a thousand-fold in one round becomes a million-fold in
two rounds of selection. Thus, even when enrichments in each round are low, multiple
rounds of affinity selection leads to the isolation of rare phage and the genetic material
contained within which encodes the sequence of the domain or motif of the recombinant
miniature protein that binds or otherwise specifically associates with it binding target.
Accordingly, in various embodiments of the invention, the methods disclosed
herein are used to produce a phage expression library encoding miniature proteins
capable of binding to a DNA or to a protein that has already been selected using the
protein grafting procedure described above. In such embodiments, phage display can be
used to identify miniature proteins that display an even higher affinity for a particular
target DNA or protein than that of the miniature proteins produced without the aid of
phage display. In yet another embodiment, the invention encompasses a universal phage
display library that can be designed to display a combinatorial set of epitopes or binding
sequences to permit the recognition of nucleic acids, proteins or small molecules by a
miniature protein without prior knowledge of the natural epitope or specific binding
residues or motifs natively used for recognition and association.
Various structural modifications also are contemplated for the present invention
that, for example, include the addition of restriction enzyme recognition sites into the
polynucleotide sequence encoding the miniature protein that enable genetic manipulation
of these gene sequences. Accordingly, the re-engineered miniature proteins can be
ligated, for example, into an M13-derived bacteriophage cloning vector that permits
expression of a fusion protein on the phage surface. These methods allow for selecting
phage clones encoding fusion proteins that bind a target ligand and can be completed in a
rapid manner allowing for high-throughput screening of miniature proteins to identify the
miniature protein with the highest affinity and selectivity for a particular target.
According to the methods of the invention, a library of phage displaying modified
miniature proteins is incubated with the immobilized target DNA or proteins to select
phage clones encoding miniature proteins that specifically bind to or otherwise
specifically associate with the immobilized DNA or protein. This procedure involves
immobilizing a oligonucleotide or polypeptide sample on a solid substrate. The bound
phage are then dissociated from the immobilized oligonucleotide or polypeptide and
amplified by growth in bacterial host cells. Individual viral plaques, each expressing a
different recombinant miniature protein, are expanded to produce amounts of protein
sufficient to perform a binding assay. The DNA encoding this recombinant binding
protein can be subsequently modified for ligation into a eukaryotic protein expression
vector. The modified miniature protein, adapted for expression in eukaryotic cells, is
ligated into a eukaryotic protein expression vector.
In another aspect, the invention encompasses miniature proteins that bind to other
proteins and methods for making these miniature proteins. The binding of the miniature
proteins modulates protein-protein and/or protein-ligand interactions. Thus, in some
embodiments the binding blocks the association (or specific binding) of ligands and
receptors. The ligand can be either another protein but also can be any other type of
molecule such as a chemical substrate. In one embodiment of the present invention,
making the protein-binding miniature protein of the invention involves determining the
amino acid residues which are essential to binding of the ligand protein to its target
receptor protein. In some embodiments, these essential residues are identified using
three-dimensional models of a protein or protein complex which binds to or interacts
with another protein based on crystallographic studies while in other embodiments they
are identified by studies of deletion or substitution mutants of the protein. The residues
that participate in binding of the protein to are then grafted onto those positions which
are not necessary to maintain the tertiary structure of the protein scaffold to form the
protein-binding miniature protein.
The miniature proteins of the present invention further include conservative
variants of the miniature proteins herein described, according to another aspect. As used
herein, a "conservative variant" refers to alterations in the amino acid sequence that do
not substantially and adversely affect the binding or association capacity of the protein.
A substitution, insertion or deletion is said to adversely affect the miniature protein when
the altered sequence prevents, reduces, or disrupts a function or activity associated with
the protein. For example, the overall charge, structure or hydrophobic-hydrophilic
properties of the miniature protein can be altered without adversely affecting an activity.
Accordingly, the amino acid sequence can be altered, for example to render the peptide
more hydrophobic or hydrophilic, without adversely affecting the activities of the
miniature protein.
These variants, though possessing a slightly different amino acid sequence than
those recited above, will still have the same or similar properties associated with any of
the miniature proteins discussed herein, for instance, SEQ ID NOs: 1-124. Ordinarily,
the conservative substitution variants, will have an amino acid sequence having at least
75%, at least 80%, at least 85%, at least 90%, at least 95% amino acid, at least 98%, or at
least 99% sequence identity with any of the miniature proteins discussed herein, for
example, SEQ ID NOs: 1-124. Identity or homology with respect to such sequences is
defined herein as the percentage of amino acid residues in the candidate sequence that
are identical with the known peptides, after aligning the sequences and introducing gaps,
if necessary, to achieve the maximum percent homology, and not considering any
conservative substitutions as part of the sequence identity. N-terminal, C-terminal or
internal extensions, deletions, or insertions into the peptide sequence shall not be
construed as affecting homology.
Thus, the miniature proteins of the present invention include molecules
comprising any of the amino acid sequences discussed herein, including SEQ ID NOs: 1-
124; fragments thereof having a consecutive sequence of at least about 15, 20, 25, 30, 35
or more amino acid residues of the miniature proteins of the invention; amino acid
sequence variants of such sequences wherein at least one amino acid residue has been
inserted N- or C-terminal to, or within, the disclosed sequence; amino acid sequence
variants of the disclosed sequences, or their fragments as defined above, that have been
substituted by another residue. Contemplated variants further include those derivatives
wherein the protein has been covalently modified by substitution, chemical, enzymatic,
or other appropriate means with a moiety other than a naturally occurring amino acid (for
example, a detectable moiety such as an enzyme or radioisotope).
The present invention further provides, in another aspect, nucleic acid molecules
that encode any of the amino acid sequences discussed herein, including any of SEQ ID
NOs: 1-124 or the related miniature proteins herein described, preferably in isolated
form. As used herein, "nucleic acid" includes cDNA and mRNA, as well as nucleic
acids based on alternative backbones or including alternative bases whether derived from
natural sources or synthesized. Those of ordinary skill in the art, given an amino acid
sequence, will be able to generate corresponding nucleic acid sequences that can be used
to generate the amino acid sequence, using no more than routine skill. As used herein, a
nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is
substantially separated from contaminant nucleic acid encoding other polypeptides from
the source of nucleic acid.
The present invention also provides fragments of the encoding nucleic acid
molecule. As used herein, a "fragment of an encoding nucleic acid molecule" refers to a
portion of the entire protein encoding sequence of the miniature protein. The size of the
fragment will be determined by the intended use. For example, if the fragment is chosen
so as to encode an active portion of the protein, the fragment will need to be large
enough to encode the functional region(s) of the protein. The appropriate size and extent
of such fragments can be determined empirically by persons skilled in the art.
Modifications to the primary structure itself by deletion, addition, or alteration of
the amino acids incorporated into the protein sequence during translation can be made
without destroying the activity of the miniature protein. Such substitutions or other
alterations result in miniature proteins having an amino acid sequence encoded by a
nucleic acid falling within the contemplated scope of the present invention.
The present invention further provides, in some embodiments, recombinant DNA
molecules that contain a coding sequence. As used herein, a "recombinant DNA
molecule" is a DNA molecule that has been subjected to molecular manipulation.
Methods for generating recombinant DNA molecules are well known in the art, for
example, see Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, Cold
Spring Harbor Laboratory Press. In some recombinant DNA molecules, a coding DNA
sequence is operably linked to expression control sequences and vector sequences.
The choice of vector and expression control sequences to which one of the
protein family encoding sequences of the present invention is operably linked depends
directly, as is well known in the art, on the functional properties desired (e.g., protein
expression, and the host cell to be transformed). A vector of the present invention may
be at least capable of directing the replication or insertion into the host chromosome, and
preferably also expression, of the structural gene included in the recombinant DNA
molecule.
Expression control elements that are used for regulating the expression of an
operably linked miniature protein encoding sequence are known in the art and include,
but are not limited to, inducible promoters, constitutive promoters, secretion signals, and
other regulatory elements. Preferably, the inducible promoter is readily controlled, such
as being responsive to a nutrient in the host cell's medium.
In one embodiment, the vector containing a coding nucleic acid molecule will
include a prokaryotic replicon, i.e., a DNA sequence having the ability to direct
autonomous replication and maintenance of the recombinant DNA molecule extra-
chromosomal in a prokaryotic host cell, such as a bacterial host cell, transformed
therewith. Such replicons are well known in the art. In addition, vectors that include a
prokaryotic replicon may also include a gene whose expression confers a detectable
marker such as a drug resistance. Typical of bacterial drug resistance genes are those
that confer resistance to ampicillin or tetracycline.
Vectors that include a prokaryotic replicon can further include a prokaryotic or
bacteriophage promoter capable of directing the expression (transcription and
translation) of the coding gene sequences in a bacterial host cell, such as E. coli. A
promoter is an expression control element formed by a DNA sequence that permits
binding of RNA polymerase and transcription to occur. Promoter sequences compatible
with bacterial hosts are typically provided in plasmid vectors containing convenient
restriction sites for insertion of a DNA segment of the present invention. Any suitable
prokaryotic host can be used to express a recombinant DNA molecule encoding a protein
of the invention.
Expression vectors compatible with eukaryotic cells, preferably those compatible
with vertebrate cells, can also be used to form recombinant DNA molecules that contains
a coding sequence. Eukaryotic cell expression vectors are well known in the art and are
available from several commercial sources. Typically, such vectors are provided
containing convenient restriction sites for insertion of the desired DNA segment.
Eukaryotic cell expression vectors used to construct the recombinant DNA
molecules of the present invention may further include a selectable marker that is
effective in an eukaryotic cell, preferably a drug resistance selection marker. An
example drug resistance marker is the gene whose expression results in neomycin
resistance, i.e., the neomycin phosphotransferase (neo) gene. Alternatively, the
selectable marker can be present on a separate plasmid, the two vectors introduced by co-
transfection of the host cell, and transfectants selected by culturing in the appropriate
drug for the selectable marker.
The present invention further provides, in yet another aspect, host cells
transformed with a nucleic acid molecule that encodes a miniature protein of the present
invention. The host cell can be either prokaryotic or eukaryotic. Eukaryotic cells useful
for expression of a miniature protein of the invention are not limited, so long as the cell
line is compatible with cell culture methods and compatible with the propagation of the
expression vector and expression of the gene product.
Transformation of appropriate cell hosts with a recombinant DNA molecule
encoding a miniature protein of the present invention is accomplished by well known
methods that typically depend on the type of vector used and host system employed.
With regard to transformation of prokaryotic host cells, electroporation and salt
treatment methods can be employed (see, for example, Sambrook et al., (1989)
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press). With
regard to transformation of vertebrate cells with vectors containing recombinant DNA,
electroporation, cationic lipid or salt treatment methods can be employed (see, for
example, Graham et al, (1973) Virology 52, 456-467; Wigler et al., (1979) Proc. Natl.
Acad. Sci. USA 76, 1373-1376).
Successfully transformed cells (cells that contain a recombinant DNA molecule
of the present invention), can be identified by well known techniques including the
selection for a selectable marker. For example, cells resulting from the introduction of a
recombinant DNA of the present invention can be cloned to produce single colonies.
Cells from those colonies can be harvested, lysed and their DNA content examined for
the presence of the recombinant DNA using a method such as that described by
Southern, (1975) J. MoI. Biol. 98, 503-517 or the proteins produced from the cell assayed
via an immunological method.
The present invention further provides, in still another aspect, methods for
producing a miniature protein of the invention using nucleic acid molecules herein
described. In general terms, the production of a recombinant form of a protein typically
involves the following steps: a nucleic acid molecule is obtained that encodes a protein
of the invention, such as the nucleic acid molecule encoding any of the miniature
proteins described herein, including any of SEQ ID NOs: 1-124. The nucleic acid
molecule may then be placed in operable linkage with suitable control sequences, as
described above, to form an expression unit containing the protein open reading frame.
The expression unit is used to transform a suitable host and the transformed host is
cultured under conditions that allow the production of the recombinant miniature protein.
Optionally the recombinant miniature protein is isolated from the medium or from the
cells; recovery and purification of the protein may not be necessary in some instances
where some impurities may be tolerated.
Each of the foregoing steps can be done in a variety of ways. The construction of
expression vectors that are operable in a variety of hosts is accomplished using
appropriate replicons and control sequences, as set forth above. The control sequences,
expression vectors, and transformation methods are dependent on the type of host cell
used to express the gene. Suitable restriction sites, if not normally available, can be
added to the ends of the coding sequence so as to provide an excisable gene to insert into
these vectors. An artisan of ordinary skill in the art can readily adapt any
host/expression system known in the art for use with the nucleic acid molecules of the
invention to produce a recombinant miniature protein.
In another aspect, the present invention provides methods for use in isolating and
identifying binding partners of the miniature proteins of the invention. In some
embodiments, a miniature protein of the invention is mixed with a potential binding
partner or an extract or fraction of a cell under conditions that allow the association of
potential binding partners with the protein of the invention. After mixing, peptides,
polypeptides, proteins or other molecules that have become associated with a miniature
protein of the invention are separated from the mixture. The binding partner bound to
the protein of the invention can then be removed and further analyzed. To identify and
isolate a binding partner, the entire miniature protein can be used. Alternatively, a
fragment of the miniature protein which contains the binding domain can be used.
As used herein, a "cellular extract" refers to a preparation or fraction which is
made from a lysed or disrupted cell. A variety of methods can be used to obtain an
extract of a cell. Cells can be disrupted using either physical or chemical disruption
methods. Examples of physical disruption methods include, but are not limited to,
sonication and mechanical shearing. Examples of chemical lysis methods include, but
are not limited to, detergent lysis and enzyme lysis. A skilled artisan can readily adapt
methods for preparing cellular extracts in order to obtain extracts for use in the present
methods.
Once an extract of a cell is prepared, the extract is mixed with the a miniature
protein of the invention under conditions in which association of the miniature protein
with the binding partner can occur. A variety of conditions can be used, the most
preferred being conditions that closely resemble conditions found in the cytoplasm of a
human cell. Features such as osmolarity, pH, temperature, and the concentration of
cellular extract used, can be varied to optimize the association of the protein with the
binding partner.
After mixing under appropriate conditions, the bound complex is separated from
the mixture. A variety of techniques can be utilized to separate the mixture. For
example, antibodies specific to a protein of the invention can be used to
immunoprecipitate the binding partner complex. Alternatively, standard chemical
separation techniques such as chromatography and density-sediment centrifugation can
be used.
After removal of non-associated cellular constituents found in the extract, the
binding partner can be dissociated from the complex using conventional methods. For
example, dissociation can be accomplished by altering the salt concentration or pH of the
mixture.
To aid in separating associated binding partner pairs from the mixed extract, the
miniature protein of the invention can be immobilized on a solid support. For example,
the miniature protein can be attached to a nitrocellulose matrix or acrylic beads.
Attachment of the miniature protein to a solid support aids in separating peptide-binding
partner pairs from other constituents found in the extract. The identified binding partners
can be either a single DNA molecule or protein or a complex made up of two or more
proteins. Alternatively, binding partners may be identified using the alkaline
phosphatase fusion assay according to the procedures of Flanagan & Vanderhaeghen,
(1998) Annu. Rev. Neurosci. 21, 309-345 or Takahashi et al., (1999) Cell 99, 59-69; the
Far-Western assay according to the procedures of Takayama et al., (1997) Methods MoI.
Biol. 69, 171-184, or Sauder et al., J. Gen. Virol. (1996) 77, 991-996 or identified
through the use of epitope tagged proteins or GST fusion proteins.
In another embodiment, the nucleic acid molecules encoding a miniature protein
of the invention can be used in a yeast two-hybrid system. The yeast two-hybrid system
has been used to identify other protein partner pairs and can readily be adapted to employ
the nucleic acid molecules herein described (see, e.g., Stratagene Hybrizap® two-hybrid
system).
According to some aspects, the miniature proteins of the invention are useful for
drug screening to identify agents capable of binding to the same binding site as the
miniature proteins. The miniature proteins are also useful for diagnostic purposes to
identify the presence and/or detect the levels of DNA or protein that binds to the
miniature proteins of the invention. In one diagnostic embodiment, the miniature
proteins of the invention are included in a kit used to detect the presence of a particular
DNA or protein in a biological sample. The miniature proteins of the invention also
have therapeutic uses in the treatment of disease associated with the presence of a
particular DNA or protein. In one therapeutic embodiment, the miniature proteins can be
used to bind to DNA to promote or inhibit transcription, while in another therapeutic
embodiment, the miniature proteins bind to a protein resulting in inhibition or
stimulation of the protein.
In some aspects of the invention, miniature proteins of the invention are
administrated to a subject in an effective amount to treat a cancer or a tumor. Non-
limiting examples of such proteins include SEQ ID NOs. 40-42, which are targeted
towards the BCL-2 pathway. Without wishing to be bound by any theory, it is believed
that such proteins may inhibit the interaction of a protein containing a BH3 death domain
(e.g., Bak or Bid) with a multidomain BCL-2 family member.
As another example, a miniature protein may inhibit (completely or partially)
migration of a tumor cell across a barrier, thereby forming an eclipse. The invasion and
metastasis of cancer is a complex process which involves changes in cell adhesion
properties which allow a transformed cell to invade and migrate through the extracellular
matrix (ECM) and acquire anchorage-independent growth properties. Some of these
changes occur at focal adhesions, which are cell/ECM contact points containing
membrane-associated, cytoskeletal, and intracellular signaling molecules. Metastatic
disease occurs when the disseminated foci of tumor cells seed a tissue which supports
their growth and propagation, and this secondary spread of tumor cells is responsible for
the morbidity and mortality associated with the majority of cancers. Thus the term
"metastasis" as used herein refers to the invasion and migration of tumor cells away from
the primary tumor site.
Miniature proteins of the invention may be administrated to cells of a subject to
treat or prevent diseases (e.g., cancers) alone or in combination with the administration
of other therapeutic compounds for the treatment or prevention of these disorders.
In certain aspects, miniature proteins of the invention are useful for diagnostic
purposes to identify the presence and/or detect the levels of a target protein that binds to
the miniature proteins of the invention. For example, miniature proteins of the invention
can be used to detect the levels of Bcl2 or hDM2 due to its high affinity and high
specifity. Miniature proteins of this method can be labeled with a detectable marker. A
wide range of detectable markers can be used, including but not limited to biotin, a
fluorogen, an enzyme, an epitope, a chromogen, or a radionuclide. The method for
detecting the label will depend on the nature of the label and can be any known in the art,
e.g., film to detect a radionuclide, an enzyme substrate that gives rise to a detectable
signal to detect the presence of an enzyme, antibody to detect the presence of an epitope,
etc.
In a specific diagnostic embodiment, miniature proteins of the invention are
included in a kit used to detect the presence of a particular protein (e.g., Bcl2 or hDM2)
in a biological sample.
In certain aspects, therapeutic compounds of the present invention (e.g.,
miniature proteins) are formulated with a pharmaceutically acceptable carrier. Miniature
proteins of the present invention can be administered alone or as a component of a
pharmaceutical formulation (composition). The compounds may be formulated for
administration in any convenient way for use in human or veterinary medicine. Wetting
agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate,
as well as coloring agents, release agents, coating agents, sweetening, flavoring and
perfuming agents, preservatives and antioxidants can also be present in the compositions.
Formulations of the miniature proteins include those suitable for oral/nasal,
topical, parenteral and/or intravaginal administration. The formulations may
conveniently be presented in unit dosage form and may be prepared by any methods well
known in the art of pharmacy. The amount of active ingredient which can be combined
with a carrier material to produce a single dosage form will vary depending upon the host
being treated, the particular mode of administration. The amount of active ingredient
which can be combined with a carrier material to produce a single dosage form will
generally be that amount of the compound which produces a therapeutic effect.
Methods of preparing these formulations or compositions include combining one
compound and a carrier and, optionally, one or more accessory ingredients. In general,
the formulations are prepared by combining a compound with a liquid carrier, or a finely
divided solid carrier, or both, and then, if necessary, shaping the product.
Formulations of the miniature proteins suitable for oral administration may be in
the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually
sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in
an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion,
or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin,
or sucrose and acacia) and/or as mouth washes and the like, each containing a
predetermined amount of a compound as an active ingredient. A compound may also be
administered as a bolus, electuary or paste.
In solid dosage forms for oral administration (capsules, tablets, pills, dragees,
powders, granules, and the like), a miniature protein is mixed with one or more
pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate,
and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose,
glucose, mannitol, and/or silicic acid; (2) binders, such as, for example,
carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia;
(3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium
carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate;
(5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as
quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl
alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9)
lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols,
sodium lauryl sulfate, and mixtures thereof; and/or (10) coloring agents. In the case of
capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering
agents. Solid compositions of a similar type may also be employed as fillers in soft and
hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as
high molecular weight polyethylene glycols and the like.
Liquid dosage forms for oral administration of a miniature protein include
pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups,
and elixirs. In addition to the active ingredient, the liquid dosage forms may contain
inert diluents commonly used in the art, such as water or other solvents, solubilizing
agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl
acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol,
tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and
mixtures thereof. Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending agents, sweetening,
flavoring, coloring, perfuming, and preservative agents.
Suspensions, in addition to the active compounds (e.g., miniature proteins), may
contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene
sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide,
bentonite, agar-agar and tragacanth, and mixtures thereof.
Methods of the invention can be administered topically in some embodiments,
either to skin or to mucosal membranes (e.g., those on the cervix and vagina). This offers
the greatest opportunity for direct delivery to tumor with the lowest chance of inducing
side effects. The topical formulations may further include one or more of the wide
variety of agents known to be effective as skin or stratum corneum penetration
enhancers. Examples of these are 2-pyrrolidone, -methyl-2-pyrrolidone,
dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol,
dimethyl sulfoxide, and azone. Additional agents may further be included to make the
formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes,
fragrances, preservatives, stabilizers, and surface active agents. Keratolytic agents such
as those known in the art may also be included. Examples are salicylic acid and sulfur.
Dosage forms for the topical or transdermal administration of a compound (e.g., a
miniature protein) include powders, sprays, ointments, pastes, creams, lotions, gels,
solutions, patches, and inhalants. The active compound may be mixed under sterile
conditions with a pharmaceutically acceptable carrier, and with any preservatives,
buffers, or propellants which may be required. The ointments, pastes, creams and gels
may contain, in addition to a therapeutic compound, excipients, such as animal and
vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives,
polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures
thereof.
Powders and sprays can contain, in addition to a compound, excipients such as
lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder,
or mixtures of these substances. Sprays can additionally contain customary propellants,
such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as
butane and propane.
Pharmaceutical compositions suitable for parenteral administration may comprise
one or more compounds in combination with one or more pharmaceutically acceptable
sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions,
or sterile powders which may be reconstituted into sterile injectable solutions or
dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats,
solutes which render the formulation isotonic with the blood of the intended recipient or
suspending or thickening agents. Examples of suitable aqueous and nonaqueous carriers
which may be employed in the pharmaceutical compositions of the invention include
water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the
like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable
organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by
the use of coating materials, such as lecithin, by the maintenance of the required particle
size in the case of dispersions, and by the use of surfactants.
Injectable depot forms are made by forming microencapsule matrices of the
compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on
the ratio of drug to polymer, and the nature of the particular polymer employed, the rate
of drug release can be controlled. Examples of other biodegradable polymers include
poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the drug in liposomes or microemulsions which are compatible with body
tissue.
Formulations of the compounds for intravaginal administration may be presented
as a suppository, which may be prepared by mixing one or more compounds of the
invention with one or more suitable nonirritating excipients or carriers comprising, for
example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which
is solid at room temperature, but liquid at body temperature and, therefore, will melt in
the rectum or vaginal cavity and release the active compound. Optionally, such
formulations suitable for vaginal administration also include pessaries, tampons, creams,
gels, pastes, foams or spray formulations containing such carriers as are known in the art
to be appropriate.
The following documents are incorporated herein by reference: U.S. Provisional
Patent Application Serial No. 61/068,259, filed March 5, 2008, entitled "Cell Permeable
Miniprotein Inhibitors of BCL2 Interactions," by A. Schepartz; U.S. Provisional Patent
Application Serial No. 61/01 1,31 1, filed January 16, 2008, entitled "Cell-Permeable
Miniature Proteins via a-Helical Arginine Display," by A. Schepartz, et al; U.S.
Provisional Patent Application Serial No. 61/009,905, filed January 3, 2008, entitled
"Intrinsically Cell-Permeable Miniature Proteins Based on a Minimal Cationic PPII
Motif," by A. Schepartz, et al; and U.S. Provisional Patent Application Serial No.
60/926,379, filed April 24, 2007, entitled "Cell Permeable Miniature Proteins," by A.
Schepartz Shrader, et al. ; U.S. Provisional Patent Application Serial No. 60/963,744,
filed August 6, 2007, entitled "Engineering a Monomeric Miniature Protein," by Hodges,
et al., incorporated herein by reference; U.S. Patent Application Serial No. 09/840,085,
filed April 24, 2001 , entitled "Modified Avian Pancreatic Polypeptide Miniature Binding
Proteins," by A.S. Shrader, et al, now U.S. Patent No. 7,297,762, issued November 20,
2007; U.S. Patent Application Serial No. 11/009,101, filed December 10, 2004, entitled
"Protein Binding Miniature Proteins and Uses Thereof," by D. Golemi-Kotra, et al,
published as U.S. Patent Application Publication No. 2005/0287643 on December 29,
2005; U.S. Patent Application Serial No. 10/982,727, filed November 4, 2004, entitled
"Protein Binding Miniature Proteins," by A.S. Shrader, et al, published as U.S. Patent
Application Publication No. 2005/0287542 on December 29, 2005; and an International
Patent Application filed on April 16, 2008, entitled "Modified Miniature Proteins," by
A.S. Schepartz, et al
The following examples are intended to illustrate certain embodiments of the
present invention, but do not exemplify the full scope of the invention.
EXAMPLE 1
This example illustrates encodable cell-penetrating peptides (CPPs) possessing
type-II polyproline (PPII) helical structure that can be embedded within the primary
sequence of a small structured protein. The marriage of arginine- and proline-rich
sequences for the generation of structured CPPs is appealing for several reasons. PPII
helices are stable in short, isolated sequence motifs. Moreover, due to its large 3.1
Angstrom rise per residue, the PPII helix readily tolerates charged side chains on
successive turns. In fact, arginine has high PPII propensity in host-guest studies,
facilitating the design of PPII helices possessing one or more cationic faces. In addition,
natural proline-rich sequences such as Bactenecin-7 (Bac) and gamma-zein (SAP)
permeate cells, albeit with low efficiency. Although non-natural amino acid
modifications can substantially increase the uptake of PPII-based CPPs, these derivatives
are not readily DNA-encodable.
To establish design rules for successfully wedding the uptake capacity of
oligoarginines to the structural propensity of oligoprolines, two series of cationic PPII
helices were synthesized. Exploiting the periodicity (3.0 residues per turn) of the left-
handed PPII helix, these minimalist repeats of (PPR)n and (PRR)n created aligned faces
of proline or arginine residues. All peptides were labeled at the N-terminus with
fluorescein, and their uptake into live HeLa cells was evaluated by flow cytometry (Fig.
3A). Fig. 3A illustrates HeLa cell uptake of 1 micromolar fluorescein-labeled peptides
after 1 h quantified by flow cytometry. This plot illustrates the mean cellular
fluorescence + the standard error of three experiments.
Neither the previously reported proline-rich sequences, SAP and Bac, nor
members of the proline-rich (PPR)n series showed significant uptake after 1 h at 1
micromolar. (PRR)3 (SEQ ID: NO: 68) and (PRR)4 (SEQ ID: NO: 69) were slightly
more cell-permeable under these conditions, performing as well as Tat. In contrast,
(PRR)5 (SEQ ID NO: 70) and (PRR)6 (SEQ ID NO: 71) were found to be extraordinarily
cell-permeable, matching or surpassing the levels observed for simple oligoarginines R8
(SEQ ID NO: 72), Ri0 (SEQ ID NO: 73), and Ri2 (SEQ ID NO: 74). The relative
efficiencies of R8, R 0, and Ri were length-dependent, consistent with earlier reports that
oligoarginine uptake increases with increasing charge but peaks between R8 and R i5
(SEQ ID NO: 75). The (PRR)n series displayed an even stronger length dependence,
such that (PRR)4 significantly underperformed its "iso-ionic" counterpart Rg, whereas
(PRR)5 matched Ri0 and (PRR)6 outperformed R 2. Thus, at longer lengths, the uptake
of simple (PRR)n peptides exceeded the maximal uptake of oligoarginine vectors,
outperforming the commonly used sequences R8 and Tat by 3-4 and 29-44 times,
respectively.
While the flow cytometry protocol used here included trypsin treatment to
remove any cell-surface bound peptide, live-cell confocal microscopy was also
performed to verify internalization and assess intracellular distribution (Fig. 3B). In this
figure, HeLa cells were incubated with 1 micromolar (PRR)5 for 20 min, and
intracellular localization was monitored by confocal microscopy. The endosomes were
visualized using 10 micromolar 10 kDa dextran labeled with AlexaFluor-647. The
peptides generated diffuse cytoplasmic and nuclear staining, as well as strong nucleoli
staining. The lack of co-localization with dextran, an endocytotic marker, revealed that
little peptide was present in the endosomes. Another requisite feature of import tags is
that they are not intrinsically cytotoxic at concentrations required for uptake. No
significant reduction was found in cell viability after a 6 h incubation with 1-100
micromolar (PPR)n and (PRR)n peptides. See Table 1 and Figs. 5A and 5B, which shows
HeLa cells were treated with varying concentrations of peptide for 6 hours, and cellular
viability determined by resazurin reduction, as described below. The standard deviation
of four independent experiments is reported.
Table 1
Peptide % Cell Viability 1 MKKMAX" Wavelength (am) %pp ιr
PPR, 102 ± IO 396 228.0 47
PPR 94 ± 10 14 229.0 46
PPR i ± i l 39 229.0 45
PPR 104 ± 3 -56 229 5 44
PRR 96 ± 2 192 228 0 46
PRR 92 ± 8 -37 228.5 4 1
PRR 99 ± 5 232 227.5 43
PRR. 104 ± H -376 229.0 42
RR3-aPP 98 ± 6
KR4<ιP 98 5
RRS aPP 9 1 8
*IO µ peptide. 6 hours. slandard deviation of four experiments; ''degHlmol (#eπi*
at 5 X ' in PBS. pli 7.4: τ ' PPII - ((MRJ\ lAX 6 1OOj/1 3.7W) ) OO
Consistent with their design, both the (PPR) n and (PRR) n series displayed
characteristic PPII signatures, with weak mean residual ellipticity (MRE) maxima at
~228 nm and strong minima at —204 nm (Fig. 3C). This figure illustrates two-color
fluorescence with bright-field superposition. The bands observed for arginine-rich
(PRR) n peptides were blue-shifted relative to proline-rich (PPR) n peptides, as expected
from the lower tertiary amide content in the former. As the positions of the maxima for
both series corresponded well to that of oligoproline peptides, the PPII content could be
approximated using Creamer's method. Both (PPR) n and (PRR) n peptides showed
extensive, temperature-dependent structure that was nearly 50% PPII helical at 5 0C and
retained approximately 20% PPII helicity at 90 0C (see Fig. 6). This figure shows the
temperature dependence of PPII helicity, with the maximum mean residue ellipticity for
each peptide (100 micromolar in PBS, pH 7.4) being plotted as a function of
temperature. PPII helicity is estimated from the maximum MRE. In comparison, a
heptaproline peptide (P7GY) was 67% PPII helical, with single amino acid substitutions
(PsXP3GY) reducing helicity to 49-66%. Fig. 3D illustrates circular dichroism spectra of
100 micromolar (PPR)n and (PRR)n peptides at 5
0C in PBS (phosphate-buffered saline),
pH 7.4.
To test the ability of the (PRR)n motif to deliver cargos both capable of
supporting functionality and dependent on PPII structure, they were incorporated into the
miniature protein avian pancreatic polypeptide (aPP) (Fig. 4A). Fig. 4A shows the
installation of (PRR)5 in a miniature protein by sequence alignment. Previous work has
shown that aPP is a robust platform for the design of miniature proteins that bind DNA
and proteins, inhibiting their interactions with high affinity and specificity in vitro and in
cells. The PPII helix of aPP was replaced with (PRR)5 to create RR5-aPP (SEQ ID NO:
47) (Fig. 4A). As measured by flow cytometry (Fig. 4B), RR5-aPP penetrated cells as
efficiently as an isolated (PRR)5 motif. RR4-aPP (SEQ ID NO: 48) and RR3-aPP (SEQ
ID NO: 49), with successively truncated N-terminal extensions, demonstrated slightly
greater cellular uptake than RR5-aPP. Notably, RR3-aPP did not add additional residues
to the native aPP sequence and was significantly more cell-permeable than arginine
homopolymers of comparable arginine content. Fig. 4B shows HeLa cell uptake of 1
micromolar fluorescein-labeled miniature proteins after 1 h quantified by flow
cytometry. This plot illustrates the mean cellular fluorescence + the standard error of
three experiments.
Confocal microscopy confirms that, like the uptake motifs in isolation, these cell-
permeable miniature proteins were intracellular and not sequestered in endosomes (Fig.
4D). In these figures, HeLa cells were incubated with 1 micromolar RR3-aPP for 20
min, and intracellular localization was monitored by confocal microscopy. The
endosomes were visualized using 10 micromolar 10 kDa dextran labeled with
AlexaFluor-647. RR3-aPP and RR4-aPP did not show discernible toxicity at 10
micromolar, while cells incubated with RR5-aPP remained 91% viable. None of the
three was cytotoxic at 1 micromolar. Circular dichroism demonstrated that, although
installation of the PPII-based CPP results in some loss of alpha-helicity, the miniature
proteins retained significant structure and thermostability (Figs. 4C and 7). RR3-aPP,
RR4-aPP, and RR5-aPP exhibited melting transitions at 44, 45, and 38 0C, respectively,
comparable to those of monomeric aPP molecules. The CD spectra were taken at 50
micromolar concentration of miniature proteins at 5 0C in PBS, pH 7.4. Fig. 7 shows the
thermostability of RR3-aPP, with the mean residue ellipticity at 222 nm of RR3-aPP (50
micromolar in PBS, pH 7.4) plotted as a function of temperature. Reported melting
temperatures correspond to the maximum of the first derivative of the MRE with respect
to temperature. Fig. 4E shows two-color fluorescence with bright-field superposition.
In summary, this example illustrates the design of encodable, cell-permeable
peptides possessing polyproline type-II structure. These motifs penetrated eukaryotic
cells with efficiencies higher than Tat and previous natural PPII peptides, and also higher
than oligoarginine peptides. These PPII-based motifs are not cytotoxic at concentrations
10-100 times greater than that necessary for uptake. Moreover, encoding the motifs
within miniature proteins endowed cell permeability without destroying structure or
adding significant mass. Thus, these motifs can facilitate both the delivery of peptides
and proteins for intracellular study, as well as expand the utility of functionalized
miniature proteins.
Additional experimental details follow. Peptide synthesis, labeling and
purification: Peptides were synthesized at the 25 micromolar scale using standard solid-
phase Fmoc chemistry on a Symphony automated solid-phase synthesizer (Protein
Technologies, Inc., Tucson, AZ). Fmoc-protected amino acid monomers, NovaSyn TGR
and Rink amide resins were purchased from Novabiochem (San Diego, CA) and N N-
Dimethylformamide (DMF), -methylmorpholine, piperidine, and trifluoroacetic acid
(TFA) from American Bioanalytical (Natick, MA). N-terminally fluorescein-labeled
peptides (Table 2) were synthesized as C-terminal carboxamides on Rink resin.
Following synthesis, the resin was washed thoroughly with DMF, N-terminally
deprotected with 20% piperidine in DMF and washed again with DMF. Fluorescein-5-
ex succinimidyl ester (5 mg, Invitrogen, Carlsbad, CA) in 1 mL DMF with 10 microliter
N -diisopropylethylamine (Sigma-Aldrich, St. Louis, MO) was added to each peptide
and coupled in the dark and under nitrogen for 2-4 hours before cleavage from the resin.
Tyrosine-labeled peptides (Table 3) and miniature proteins were synthesized on 25
micromoles of Tentagel TGR resin as C-terminal carboxamides and Ν-terminally
acetylated.
All peptides were purified by reverse-phase HPLC on Vydac C8 (300 Angstrom
silica, 10 micrometer particle diameter) or Cl 8 (300 Angstrom silica, 5 micrometer
particle diameter) preparative or semi-preparative columns over water/acetonitrile
gradients containing 0.1% TFA. Peptide purity was verified by reinjection on C8 or Cl 8
reverse phase analytical columns. Molecular masses (Tables 2 and 3) were quantified on





Name Sequence (Da) (Da)
SAP Flu-VRLPPPVRLPPPVRLPPP (SEQ ID NO: 76) 2473 2479
Bac Flu-GPRPLPFPRPG (SEQ ID NO: 77) 1666 1670
Tat Flu-GRKKRRQRRRPPQ (SEQ ID NO: 78) 2195 2195
R8 Flu-GRRRRRRRR (SEQ ID NO: 79) 1800 1799
RlO Flu-GRRRRRRRRRR (SEQ ID NO: 80) 2 112 2 112
R12 Flu-GRRRRRRRRRRRR (SEQ ID NO: 81) 2425 2425
PPR3 Flu-GPPRPPRPPR (SEQ ID NO: 82) 1602 1605
PPR4 Flu-GPPRPPRPPRPPR (SEQ ID NO: 83) 1952 1956
PPR6 Flu-GPPRPPRPPRPPRPPRPPR (SEQ ID NO: 84) 2653 2656
PRR3 Flu-GPRRPRRPRR (SEQ ID NO: 85) 1779 1783
PRR4 Flu-GPRRPRRPRRPRR (SEQ ID NO: 86) 2189 219 3
PRR5 Flu-GPRRPRRPRRPRRPRR (SEQ ID NO: 87) 2598 2599
PRR6 Flu-GPRRPRRPRRPRRPRRPRR (SEQ ID NO: 88) 3008 301 1
aPP GPSQPTYPGDD APVEDLIRFYNDLQQYLNVVTRHRYC-FIU 4771 4773
(SEQ ID NO: 89)
RR3-aPP GPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC-Flu 4999 5002
(SEQ ID NO: 90)
RR4-aPP RRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC-Flu 5254 5256
(SEQ ID NO: 91)
RR5-aPP RRPRRPRRPRRPGRRAPVEDLIRFYNDLQQYLNWTRHRYC-Flu 5663 5670




Name Sequence (Da) (Da)
PPR3 PPRPPRPPRY (SEQ ID NO: 93) 1275 1 273
PPR4 PPRPPRPPRPPRY (SEQ ID NO: 94) 1625 1624
PPR 5 PPRPPRPPRPPRPPRY (SEQ ID NO: 95) 1975 1974
PPR6 PPRPPRPPRPPRPPRPPRY (SEQ ID NO: 96) 2326 2326
PRR3 PRRPRRPRRY (SEQ ID NO: 97) 1452 1450
PRR4 PRRPRRPRRPRRY (SEQ ID NO: 98) 1861 1861
PRR 5 PRRPRRPRRPRRPRRY (SEQ ID NO: 99) 2271 2271
PRR6 PRRPRRPRRPRRPRRPRRY (SEQ ID NO: 100) 2680 2682
aPP GPSQPTYPGDD APVEDLIRF YNDLQQ YLNVVTRHRYC- AC4441 4437
(SEQ ID NO: 101)
RR3-aPP GPRRPRRPGRRAP VEDLIRF YNDLQQ YLNV VTRHRYC- Ac4668 4665
(SEQ ID NO: 102)
RRi-aPP RRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC-Ac 4924 4923
(SEQ ID NO: 103)
RR5-aPP RRPRRPRRPRRPGRRAPVEDLIRFYNDLQQYLNWTRHRYC-Ac 5333 5334
(SEQ ID NO: 104)
Following purification, the C-terminal cysteine of aPP-based peptides was either
fluorescein-labeled or capped with iodoacetamide to prevent disulfide formation.
Fluorescein labeling was carried out by dissolving peptide to approximately 0.3 mM in
1:5 DMF:H 2O with 10 mM phosphate buffer, pH 7.25. Iodoacetamidofluorescein (10
eq., 50 mM) in DMF was then added and allowed to react for 1-2 hours at room
temperature. Acetamide labeling was conducted by reacting 20 equivalents of
iodoacetamide (10 micromoles) with peptide (500 nmol, 0.2-0.5 mM) in PBS buffer, pH
7.4 for 1 hour at room temperature. Both reactions were stopped by flash freezing to -80
0C and stored frozen until purified by reverse-phase HPLC. Non-fluorescent peptide
concentrations were calculated using tyrosine absorption in 6 M guanidinium
hydrochloride, 20 mM sodium phosphate, pH 6.5, while fluorescent peptide
concentrations were determined using fluorescein absorption in 8 M urea, 100 mM Tris-
HCl, pH 9.0.
Flow cytometry: The uptake of fluorescently labeled peptides by live HeLa cells
was quantified by flow cytometry. HeLa cells (American Type Culture Collection,
Manassas, VA) were grown in T-75 culture flasks containing High-Glucose Dulbecco's
Modified Eagle Medium (DMEM) (Invitrogen # 11995) supplemented with 10% fetal
bovine serum (Invitrogen) (DMEM+) to -80% confluency, washed twice with 37 0C PBS
(140 mM sodium chloride, 3 mM potassium chloride, 10 mM phosphate, pH 7.4), and
incubated with 10 mL of PBS-based non-enzymatic cell dissociation solution (Chemicon
International, Temecula, CA) for 15 minutes. Cells were then collected at 500g,
resuspended in DMEM+, counted by hemocytometer and diluted to 2083 cells/microliter
with DMEM+. Aliquots of cells (240 microliters) were then added to fluorescein-labeled
peptides (10 microliters, 25 micromolar in water) to give 2-5 x 105 cells in DMEM+
containing 1 micromolar peptide. Cells were incubated with peptide for 60 minutes at 37
0C before washing twice with 500 microliters 37 0C PBS to remove extracellular peptide.
To ensure removal of any surface-bound peptide, the cells were then incubated with
0.05% trypsin at 37 0C for 10 minutes, washed with DMEM+ and then 4 0C PBS.
Finally, the cells were resuspended in 500 microliters PBS containing 1 microgram/mL
propidium iodide, and analyzed on a BD FACScan (BD Biosciences, San Jose, CA)
equipped with a 488 nm Argon laser.
A total of 30,000 events were collected, monitoring fluorescein and propidium
iodide with 530/30 bandpass and 650 longpass filters, respectively. Events
corresponding to cellular debris were removed by gating on forward and side scatter,
while dead cells are removed by propidium iodide staining. Geometric means were then
calculated from the histogram of fluorescence intensity, and corrected for background
cellular fluorescence by subtracting the geometric mean of mock-treated cells. The
standard error for the average of geometric means for three separate experiments is
reported.
Confocal microscopy: To verify the internalization of fluorescently labeled
peptides and determine their intracellular localization, live cell confocal microscopy was
employed. Approximately 105 HeLa cells were seeded in 2 mL DMEM+ into 6-well
plates containing cover glasses. After allowing the cells to adhere for at least 24 hours,
media was removed by aspiration and the cells washed twice with 37 0C PBS.
Incubation was performed by floating inverted cover glasses on 200 microliters of
DMEM + containing 1 micromolar peptide and/or 10 micromolar 10 kDa dextran labeled
with AlexaFluor 647 (Invitrogen) for 20-30 minutes at 37 0C. Cover glasses were then
washed with 37 0C DMEM +, PBS, and PBS containing 1 microgram/mL anti-fluorescein
rabbit polyclonal IgG antibody (Invitrogen #A889) to quench extracellular fluorescence.
After mounting the cover glasses on microscope slides, cells were imaged on an LSM
510 Meta (Carl Zeiss Microimaging, Thornwood, NY), using a 488 nm Ar laser line with
a 525/25 nm filter or 633 nm HeNe laser line with a 680/30 filter for visualizing
fluorescein and AlexaFluor 647, respectively.
Cellular viability assays: To determine the potential toxicity of the cell-
penetrating peptides, the reduction of resazurin to resorufin was monitored by
fluorescence using the CellTiter-Blue ® Cell Viability Assay (Promega, Madison, WI).
HeLa cells (5000 cells/well) in DMEM + were seeded into 96-well plates and allowed to
adhere overnight. Non-fluorescent peptides (12.5 microliters) were then added at a
concentration appropriate to bring the well to 1, 10 or 100 micromolar peptide. After 6
hours at 37 0C, CellTiter- Blue ® reagent (20 microliters in 40 microliters DMEM +) was
added and cells incubated for another 2 hours. Fluorescence was monitored on an
Analyst™ AD 96-384 fluorescence plate reader (LJL Biosystems) using 530/25
excitation and 580/10 emission filters. Fluorescence values were then corrected for
CellTiter-Blue background fluorescence by subtracting the reading of parallel-
processed cell-free wells. Cell viability was calculated as the percentage of peptide-
treated cells to buffer-treated cells. As a control, standard curves (created by seeding 0-
5000 cells/well) were used to corroborate the linearity of this assay. The mean viability
with standard deviation of four independent experiments, each containing at least three
replicates, was reported (Table 1, Fig. 5).
Circular dichroism: Structural characterization of non-fluorescent peptides was
accomplished by acquiring circular dichroism (CD) spectra on a Jasco J-810
Spectropolarimeter (Jasco, Tokyo, Japan) equipped with a Peltier temperature-control
module. All peptides were characterized in PBS, pH 7.4 using 100 micromolar model
peptides or 50 micromolar miniature proteins in a 2 mm cuvette. Wavelength-dependent
spectra were acquired as the average of five scans at 5 0C from 260 to 190 nm at 100
nm/min, sampling every 0.5 nm with a 1 nm bandwidth. Mean residue ellipticity (MRE)
was calculated as MRE = (Θpeptjde - Θbuffer)/(£ c x ri), where Θ is the observed signal in
degrees, L is the path length in cm, c is the concentration of peptide in dmol/cm 3 and n is
the number of residues.
To chart the temperature-dependence of PPII structure, abbreviated wavelength
scans were acquired as the average of scans from 235-210 nm at 5 0C and 10° intervals
from 10-90 0C. Data collection parameters were otherwise identical to those described
above. MRE values at the wavelength corresponding to maximal ellipticity at 5 0C were
plotted as a function of temperature. The positions of the peak closely match those
reported elsewhere, and the percentage of PPII helicity (%PPII) was estimated as
follows: %PPII = ((MREMAX + 6100)/13,700) x 100, where MREMAX is the
maximum mean residue ellipticity of the PPII peak in this region (Table 1).
To determine the temperature dependence and melting temperature (Tm) of aPP-
based molecules, the MRE was monitored at 222 nm (MRE222) from 5
0C to 90 0C. Data
were collected with a 1.0 0C data pitch, 10 s delay time, 60 °C/hour temperature slope
and 1 nm bandwidth. Melting temperatures were determined from the maximum of the
first derivative of the mean residue ellipticity (δMRE222/δT), and were 44, 45 and 38 0C
for RR3-aPP, RH4-aPP, and RR5-aPP, respectively.
EXAMPLE 2
This example illustrates that a smaller cationic motif can be embedded within the
alpha-helix of a small, folded protein to generate molecules that penetrate cells
significantly more efficiently than oligoarginine-rich sequences or Tat. These results
suggest that the function of cell permeability can be encoded by judicious placement of
as few as 2-3 additional arginine residues on a protein alpha-helix.
The avian pancreatic polypeptide (aPP) is a 36-residue polypeptide composed of
an N-terminal PPII helix and a C-terminal alpha-helix. See Fig. 8A; residues that
contribute to aPP/YY2 folding are indicated by brackets, and arginines located on the
alpha-helices are indicated by underlining. This well-packed, thermostable structure
provides a starting point for the presentation of well-folded PPII and alpha-helical
epitopes that bind protein targets with high affinity and specificity in vitro and in vivo. It
was reasoned that substitution of arginines for residues located on the aPP alpha-helix
would impart cell permeability, but perhaps only at the expense of structural stability due
to charge-charge repulsion. To determine the minimum number of arginine residues that
would facilitate cell permeability and retain a stable fold, aPP variants aPP4R1 (SEQ ID
NO: 23), aPP5R1 (SEQ ID NO: 22), and aPP6R1 (SEQ ID NO: 21) were synthesized (Fig.
8). These molecules contained four, five, or six arginines, respectively, on the solvent-
exposed face of the aPP alpha-helix in place of side chains that contribute minimally, if
at all, to protein stability. See Table 4.
Table 4
aPP GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY
(SEQ ID NO: 1)
a P p
4Ri GPSQPTYPGDDAPVRDLIRFYRDLQRYLNVVTRHRY
(SEQ ID NO: 23)
a P p
5Ri GPSQPTYPGDDAPVRDLIRFYRDLRRYLNVVTRHRY
(SEQ ID NO: 22)
a P p
6Ri GPSQPTYPGDDAPVRDLRRFYRDLRRYLNVVTRHRY
(SEQ ID NO: 21)
YY2 APPLPPRNRGEDASPEELSRYYASLRHYLNLVTRQRY
(SEQ ID NO: 67)
YY23R1 APPLPPRNRGEDASPEELSRYYRSLRHYLNLVTRQRY
(SEQ ID NO: 50)
YY24R1 APPLPPRNRGEDASPRELSRYYRSLRHYLNLVTRQRY
(SEQ ID NO: 51)
YY25R1 APPLPPRNRGEDASPRELRRYYRSLRHYLNLVTRQRY
(SEQ ID NO: 52)
R8Y RRRRRRRRY
(SEQ ID NO: 117)
Tat (48-60) GRKKRRQRRRPPQY
(SEQ ID NO: 118)
Penetratin RQIKIWFQNRRMKWKK
(SEQ ID NO: 119)
Transportan GWTLNSAGYLLKINLKALAALAKKIL
(SEQ ID NO: 120)
KLA KLALKLALKALKAALKLA
(SEQ ID NO: 121)
The secondary structure of each variant was characterized using circular
dichroism (CD) spectroscopy (Fig. 8B). This figure shows circular dichroism spectra of
aPP, aPP 4R1 , aPP 5R1 , and aPP 6R1 (10 micromolar) in PBS (pH 7.4) at 37 0C. The CD
spectra of aPP 4RI and aPP 5R1 were virtually identical to that of aPP, with characteristic
negative ellipticity at 208 and 222 nm. By contrast, the spectrum of aPP 6RI indicated
significantly less alpha-helix structure. Temperature-dependent CD analysis
demonstrated that each peptide, like aPP, underwent a cooperative melting transition.
Each arginine substitution decreases thermostability slightly, with aPP 4RI and aPP 5R1
characterized by r m' s of 54 and 47
0C, near that of aPP; the Tm of aPP
6R1 is significantly
depressed (35 0C) (Fig. 11). Referring now to Fig. 11, which shows circular dichroism
analysis of miniature protein thermostability, Fig. 1IA illustrates the temperature
dependence of the negative ellipticity at 222 nm of the indicated peptides (10
micromolar) in PBS buffer (pH 7.4). Fig. 1IB shows the first derivative OfMRE 222 nm
with respect to temperature (units are deg cm2 dmol 1 K 1) .
Next, flow cytometry was used to determine whether aPP 4RI , aPP 5R1 , and/or
aPP R penetrated eukaryotic cells. HeLa cells were incubated with 1 micromolar
fluorescein-labeled peptide for times between 5 min and 90 min and treated with trypsin
to remove peptide from the cell surface. Cellular penetration of FluaPP 5R1 (SEQ ID NO:
106), FluaPP 6R1 (SEQ ID NO: 107), and the well-studied oligoarginine FluR8Y (SEQ ID
NO: 112) were similar at early times (t < 20 min) (Fig. 9A). Fig. 9A shows the time-
dependent uptake of 1 micromolar fluorescein-labeled peptides by HeLa cells as
quantified by flow cytometry. This plot illustrates the mean cellular fluorescence + the
standard error of three experiments.
Surprisingly, uptake of FluR8Y remained constant at longer times whereas uptake
of FluaPP 5R1 and Flua PP
6R1 increased significantly. At an incubation time of 30 min,
Fiua P p4Ri S E Q I D N 0 . 105 entered cells more efficiently m a n
FluTat (SEQ ID NO: 113)
but less efficiently than FluR8Y,
FlupAntp (SEQ ID NO: 114), FluTransportan (SEQ ID
NO: 115), and FluKLA(SEQ ID NO: 116) (also known as MAP) (Fig. 8C). This figure
shows the mean cellular fluorescence of HeLa cells incubated for 30 min with 1







6Ri pene tr a ted cells significantly more effectively than any cell
penetrating peptide tested, generating cellular fluorescence 3-4 times that of FluR Y and
35-45 times that of FluTat. Confocal microscopy confirmed that Flua pp
6R1 was
internalized to the cytosol and endosomes and was not limited to the cellular membrane
(Fig. 9C).
The mechanism by which cationic peptides enter cells is not well understood and
may vary depending on sequence, conditions, and cargo. Recent results obtained with








wag both temperature . ATP-dependent (Fig. 9B). This figure
shows HeLa cells were incubated with 1 micromolar peptide for 30 min at 37 0C, 4 0C,
and at 37 0C in glucose-free media supplemented with NaN3, and intracellular
localization was quantified by flow cytometry.
Moreover, confocal microscopy of cells treated with FluaPP6R1 revealed a punctate
pattern of fluorescence in the cytosol (Fig. 9C) that colocalizes in part with 10 kDa
dextran, a marker for endocytosis (Figs. 9D and 9E). In particular, this figure shows
confocal microscopy of HeLa cells co-incubated with 5 micromolar FluaPP6R1 (Green)
and 10 kDa dextran labeled with Alexa Fluor 647 (red) for 30 min at 37 0C. Fig. 9C
illustrates the green channel, while Fig. 9D illustrates the red channel and Fig. 9E is the
superposition of Figs. 9C, 9D, and transmitted light. Together these data suggest a
significant contribution from an energy-dependent mechanism such as endocytosis.
However, Flua pp
6RI
a iso shows diffuse cytosolic staining that is not colocalized with
dextran, suggesting either endosomal escape or an alternative entry pathway.
Oligoarginine tags can increase cytotoxicity, and thus the toxicity of all peptides
was examined using the CellTiter-Blue cell viability assay (Promega). Incubation of
HeLa cells with any of the aPP- or YY2-based peptides at concentrations as high as 50
micromolar (50-fold higher than required for penetration) for 6 h (70-fold longer than
necessary for uptake) led to less than 10% loss in viability (Fig. 12). In this figure, Fig.
12A is a circular dichroism analysis of YY2 and arginine-rich variants (10 micromolar,
37 0C) in PBS buffer (pH 7.4). Fig. 12B illustrates the temperature dependence of
MRE222, while Fig. 12C illustrates the first derivative of MRE
222 with respect to
temperature (units are deg cm2 dmol 1 K 1) .
Example 1 describes a series of miniature proteins that made use of their PPII
helix to bind SH3 domains selectively in vitro; one such molecule, YY2, activated Hck
kinase in cell extracts. To evaluate whether a minimal cationic motif could be
transferred from aPP to an alternative protein context, YY23R1 , YY24R1 , and YY25R1
were synthesized (Fig. 8A). Although Fluγ γ 23R1 (SEQ ID NO: 109) did not penetrate
cells appreciably at 1 micromolar, Fluγ γ 24R1 (SEQ ID NO: 110) and Fluγ γ 25R1 (SEQ ID
NO: 111) did so at levels similar to Flua PP
6R1 (SEQ ID NO: 107), the most cell-permeant
aPP derivative studied (Fig. 8C). Unexpectedly, even FluYY2 (SEQ ID NO: 108), whose
sequence contains only two arginine residues within the alpha-helix, penetrates cells,
albeit at higher concentration. At 6 micromolar, FluYY2 shows intracellular fluorescence
twice that of FluR8Y (Fig. 10A). This figure shows HeLa cell uptake of fluorescein-
labeled peptides at the indicated concentration after 30 min at 37 0C as quantified by
flow cytometry, and this observation highlights the expanding utility of miniature
proteins, which, like certain peptoids, may not require additional engineering to offer cell
permeability. In Fig. 1OA, the figure is a plot illustrating the mean cellular fluorescence
(the standard error of three experiments. Fig. 1OB is a confocal microscopy image of
HeLa cells incubated
with 5 micromolar FluYY2 for 30 min at 37 0C.
In summary, this example illustrates the creation of a second family of minimally
cationic miniature proteins that effectively cross the plasma membrane of eukaryotic
cells. Although introduction of multiple arginine residues decreases the value of Tu,
judicious placement and empirical charge minimization afford miniature proteins that are
both well-folded and cell permeable. Thus, these scaffolds are capable of supporting
high affinity and specificity interactions in vitro and in vivo.
Additional experimental details follow. Peptide synthesis: All peptides were
synthesized using standard solid-phase Fmoc chemistry on a 25 micromole scale with a
Symphony ® multi-channel solid phase synthesizer (Protein Technologies, Inc., Tuscon,
AZ). All alpha-amino acids and resins were purchased from Novabiochem (San Diego,
CA) and solvents were purchased from American Bioanalytical (Natick, MA). All
peptides were synthesized to carry free amines at their N-termini and carboxamides at
their C-termini. Peptides were labeled on their N-termini on resin for at least one hour
with fluorescein-5-EX, succinimidyl ester (Invitrogen, Carlsbad, CA, Cat. # F-6130),
which was dissolved in 1 mL DMF and added to the reaction vessel with 20 microliters
N, -diisopropylethylamine (EDIPA).
Purification: The peptides were purified by reverse-phase HPLC using Grace
Vydac C8 preparative or semi-preparative scale columns (300 Angstrom silica, 10
micrometer particle size, 22 mm x 250 mm) and water/acetonitrile gradients containing
0.1% TFA. Peptide identity was confirmed by mass spectrometry on an Applied
Biosystems Voyager-DE Pro MALDI-TOF mass spectrometer (Foster City, CA). Once
purified, peptides were lyophilized to dryness, dissolved in water and stored at -20 0C.
Labeled peptides were protected from light.
Concentration determination: The concentration of each fluorescently labeled
peptide or miniature protein stock solution was determined by measuring the fluorescein
absorption at 500 nm in 8 M urea, 100 mM Tris-HCl (pH 9.0). Concentration was




o L), where A
5O0
is the absorbance at 500 nm, C500 is the molar extinction coefficient at 500 nm (86000 M
'cm ' 1 (Invitrogen)), and L is the path length ( 1 cm). The concentration of the unlabeled
KLA peptide was calculated by the mass to volume ratio. The concentrations of the
other non-labeled peptides were calculated by monitoring the absorbance at 280 nm in 8
M urea, 100 mM Tris-HCl (pH 7.4). Concentration was determined using the following
formula: Concentration (M) = A2 oZ(C28O L), where A280 is the absorbance at 280 nm, G280
is the molar extinction coefficient at 280 nm, calculated for each peptide sequence), and
Z, is the path length ( 1 cm). Table 5 shows calculated masses of labeled and unlabeled




Calculated (Da) Observed (Da) Calculated (Da) Observed
(Da)
aPP 4238.6 4244.1 4712.1 4718.7
aPP 4R1 4335.8 4340.2 481 1.3 4819.0
aPP 5R1 4363.9 4357.7 4839.4 4847.0
a pp6R. 4406.9 4410.5 4882.4 4889.3
YY2 4386.9 4385.4 4862.4 4855.2
YY23R1 4472.0 4476.5 4947.5 4950.6
γ γ 24Rl 4491.1 4496.4 4974.6 4979.7
YY2 5R1 4568.2 4563.6 5043.7 5051.4
R8Y 1430.7 1429.2 1906.2 1910.0
Tat 1882.2 1884.9 2357.7 2363.2
Penetratin 2246.7 2250.9 2722.2 2726.9
Transportan 2784.4 2787.7 3259.9 3265.2
KLA 1876.5 1877.7 2352.0 2351.8
Circular dichroism: Circular dichroism spectra were measured on a Jasco J- 810-
150S Spectropolarimeter (Jasco, Tokyo, Japan) equipped with a Peltier temperature-
control module and analyzed using Spectra Manager software v .1.53.01 . Spectra were
acquired at peptide concentrations of 10 micromolar in PBS (pH 7.4) in a 2 mm cuvette.
Wavelength-dependent spectra were acquired from 260 nm to 190 nm (data pitch 0.5 nm,
scan speed 50 nm/min, 4 sec, 1 nm bandwidth and 3 accumulations). Thermal
denaturation was monitored at 222 nm as the temperature was raised from 5 0C to 85 0C
using the variable temperature model (data pitch 1 0C, 5 second delay, temperature slope
1 °C/min, 4 sec response, 1 nm bandwidth, continuous scan mode). Renaturation from
85 0C to 5 0C was then performed to verify that the melting transitions were reversible.
Mean residue ellipticity values were calculated from the equation MRE = (Θsampie -
Θbuffer)/(-£ c ή) where Θ is observed signal in millidegrees, L is the length of the cuvette
in cm, c is the concentration of peptide in dmol/cm 3, and n is the number of amino acid
residues in the peptide. The melting temperature (Tm) was estimated by the inflection
point of the melt, as determined by the peak of the graph of the first derivative of the
curve (calculated by Spectra Manager software). Melting temperatures for aPP, aPP 4R1 ,
aPP 5R1 , aPP 6R1 , YY2, and YY2 3R1 are presented in Table 6, showing observed melting
temperature as determined by circular dichroism at 10 micromolar in PBS, pH 7.4.









Flow cytometry: HeLa cells (American Type Culture Collection, Manassas, VA)
were grown at 37 0C in an atmosphere containing 5% CO2 in an IR Autoflow CO2 water
incubator (Nuaire, Plymouth, MN). Cells were grown in T-75 culture flasks (BD Falcon,
Cat. #353134) containing High-Glucose Dulbecco's Modified Eagle Medium (Gibco
Cat. # 11995-065) containing 10% Fetal Bovine Serum (Gibco Cat. # 26140-079),
hereinafter called DMEM*. Cells were passaged every 5-7 days before reaching
confluency, as determined by visual inspection. For flow cytometry experiments, four
flasks of cells were grown to -90% confluency, the media was removed, and the cells
were washed twice with 10 mL/flask 37 0C PBS (140 mM NaCl, 3 mM KCl, 10 mM
phosphate, pH 7.4). The cells were dissociated from the flask surface by incubation for
15 min with 5 mL/flask Non-Enzymatic Cell Dissociation Solution (Sigma, Cat. #
C5914) at 37 0C. Cells were collected at 500g, resuspended in 5 mL DMEM*, and
counted by hemocytometer. Cells at a maximum concentration of 2000 cells/microliter
were added in aliquots of 240 microliters to aliquots of 10 microliters peptides in water
and incubated 30 min at 37 0C. Cells were collected at 500g, washed twice with 500
microliters 37 0C PBS and incubated at 37 0C with 500 microliters of 0.05% (vv/v) trypsin
to remove any surface-bound peptide. Cells were collected at 500g, washed with 500
microliters 4 0C PBS, and were resuspended in 500 microliters 4 0C PBS containing 1
microgram/mL propidium iodide (Sigma-Aldrich Cat. # P4864). Flow cytometry was
performed on a BD FACScan (Becton Dickenson, Franklin Lakes, NJ, settings: FSC E-I
7 Lin, SSC 300 1.8 Lin, F l 520 Log, F2 288 Log, F3 500 Log), collecting 10,000 events
and monitoring fluorescein and propidium iodide fluorescence with 530/30 bandpass and
650 longpass filters, respectively. Analysis was performed using FlowJo software
(v6.4.7).
Cell debris and dead cells were gated out first by forward- and side-scatter and
then by propidium iodide fluorescence. The geometric mean of the fluorescein
fluorescence of the remaining cells was calculated. The standard error, as calculated
from at least three independent trials on different days, is reported. Experiments
examining the effect of temperature and energy depletion were conducted in media that
did not contain FBS. Cells (2000 cells/microliters) were incubated in 4 0C DMEM , 37
0C DMEM, or 37 0C DMEM containing 10 mM NaN 3 and 50 mM 2-deoxy-D-glucose,
for 30 minutes prior to the addition of peptides.
Confocal microscopy: Live cell fluorescence microscopy was employed to
confirm the internalization of fluorescently labeled peptides and determine their
intracellular localization. HeLa cells were grown as described above. The day prior to
experiments, 105 cells/well were seeded into 6-well plates containing microscope cover
slips and 3 mL DMEM*. After allowing the cells to adhere for at least 24 hours, the
media was replaced and to the cells was added 5 micromolar of a fluorescently labeled
peptide/miniature protein and/or 5 micromolar 10 kDa dextran labeled with AlexaFluor
647 (Invitrogen) in DMEM*. The cells were incubated for 30 min, washed for 15 min in
DMEM*, and rinsed with PBS. The cover slips were mounted onto microscope slides
immediately before imaging on a LSM 510 Meta (Carl Zeiss Microimaging, Thornwood,
NY), visualizing fluorescein with a 488 nm Ar laser with a 525/25 nm bandpass filter
and AlexaFluor 647 with a 633 nm HeNe laser with a 680/30 bandpass filter.
Cell viability: HeLa cells were grown as described above. The day prior to
initiating experiments, cells were removed with 0.05% (w/v) trypsin (Gibco Cat. #
25200-056), and 5000 cells/well were seeded into 96-well, black surface/clear flat
bottom plates (Corning Cat. # 3603) in 45 microliters DMEM*. Control wells
containing between 0 and 5000 cells/well were also seeded. After allowing the cells to
adhere for at least 24 h , non-fluorescent peptides were added (5 microliters) to a final
volume of 50 microliters and final concentrations of 10 or 50 micromolar. After 6 h at
37 0C, 70 microliters of a 5:2 mixture of DMEM* to CellTiter-Blue ® (Promega Cat. #
6808A) was added to each well (final volume = 120 microliters). The cells were
incubated for an additional 2 h at 37 0C and the fluorescence measured on an Analyst™
AD 96-384 spectrofluorimeter (Molecular Devices, Sunnyvale, CA) using 530/25
excitation and 580/10 emission filters. Each reading was corrected to eliminate the
contribution from CellTiter-Blue ® background fluorescence by subtracting the
fluorescence of cell-free wells from the value recorded. All experiments were performed
in triplicate. The percent of viable cells (%V) was calculated as the percentage of
peptide treated-cells to that of parallel-processed water-treated cells according to the
equation: %V = (FPeptlde-Fbiank)/(Fwater-Fbiank) where Fpept.de is the fluorescence of peptide-
treated cells, Fwater is the fluorescence of water-treated cells, and Fbiank is the fluorescence
of CellTiter-Blue ®-treated wells that lacked cells (cell-free wells). Each plate was read
three times and the readings averaged. Standard error, as calculated from three separate
trials on three different days, is reported in Fig. 13, showing the percent of viable cells
(%V) after 6 h incubation at 37 0C with the indicated peptide or miniature protein at
either 10 micromolar (lighter bars) or 50 micromolar (darker bars). Error bars represent
standard error.
While several embodiments of the present invention have been described and
illustrated herein, those of ordinary skill in the art will readily envision a variety of other
means and/or structures for performing the functions and/or obtaining the results and/or
one or more of the advantages described herein, and each of such variations and/or
modifications is deemed to be within the scope of the present invention. More generally,
those skilled in the art will readily appreciate that all parameters, dimensions, materials,
and configurations described herein are meant to be exemplary and that the actual
parameters, dimensions, materials, and/or configurations will depend upon the specific
application or applications for which the teachings of the present invention is/are used.
Those skilled in the art will recognize, or be able to ascertain using no more than routine
experimentation, many equivalents to the specific embodiments of the invention
described herein. It is, therefore, to be understood that the foregoing embodiments are
presented by way of example only and that, within the scope of the appended claims and
equivalents thereto, the invention may be practiced otherwise than as specifically
described and claimed. The present invention is directed to each individual feature,
system, article, material, kit, and/or method described herein. In addition, any
combination of two or more such features, systems, articles, materials, kits, and/or
methods, if such features, systems, articles, materials, kits, and/or methods are not
mutually inconsistent, is included within the scope of the present invention.
All definitions, as defined and used herein, should be understood to control over
dictionary definitions, definitions in documents incorporated by reference, and/or
ordinary meanings of the defined terms.
The indefinite articles "a" and "an," as used herein in the specification and in the
claims, unless clearly indicated to the contrary, should be understood to mean "at least
one."
The phrase "and/or," as used herein in the specification and in the claims, should
be understood to mean "either or both" of the elements so conjoined, i.e., elements that
are conjunctively present in some cases and disjunctively present in other cases.
Multiple elements listed with "and/or" should be construed in the same fashion, i.e., "one
or more" of the elements so conjoined. Other elements may optionally be present other
than the elements specifically identified by the "and/or" clause, whether related or
unrelated to those elements specifically identified. Thus, as a non-limiting example, a
reference to "A and/or B", when used in conjunction with open-ended language such as
"comprising" can refer, in one embodiment, to A only (optionally including elements
other than B); in another embodiment, to B only (optionally including elements other
than A); in yet another embodiment, to both A and B (optionally including other
elements); etc.
As used herein in the specification and in the claims, "or" should be understood
to have the same meaning as "and/or" as defined above. For example, when separating
items in a list, "or" or "and/or" shall be interpreted as being inclusive, i.e., the inclusion
of at least one, but also including more than one, of a number or list of elements, and,
optionally, additional unlisted items. Only terms clearly indicated to the contrary, such
as "only one of or "exactly one of," or, when used in the claims, "consisting of," will
refer to the inclusion of exactly one element of a number or list of elements. In general,
the term "or" as used herein shall only be interpreted as indicating exclusive alternatives
(i.e. "one or the other but not both") when preceded by terms of exclusivity, such as
"either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when
used in the claims, shall have its ordinary meaning as used in the field of patent law.
As used herein in the specification and in the claims, the phrase "at least one," in
reference to a list of one or more elements, should be understood to mean at least one
element selected from any one or more of the elements in the list of elements, but not
necessarily including at least one of each and every element specifically listed within the
list of elements and not excluding any combinations of elements in the list of elements.
This definition also allows that elements may optionally be present other than the
elements specifically identified within the list of elements to which the phrase "at least
one" refers, whether related or unrelated to those elements specifically identified. Thus,
as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A
or B," or, equivalently "at least one of A and/or B") can refer, in one embodiment, to at
least one, optionally including more than one, A, with no B present (and optionally
including elements other than B); in another embodiment, to at least one, optionally
including more than one, B, with no A present (and optionally including elements other
than A); in yet another embodiment, to at least one, optionally including more than one,
A, and at least one, optionally including more than one, B (and optionally including other
elements); etc.
It should also be understood that, unless clearly indicated to the contrary, in any
methods claimed herein that include more than one step or act, the order of the steps or
acts of the method is not necessarily limited to the order in which the steps or acts of the
method are recited.
In the claims, as well as in the specification above, all transitional phrases such as
"comprising," "including," "carrying," "having," "containing," "involving," "holding,"
"composed of," and the like are to be understood to be open-ended, i.e., to mean
including but not limited to. Only the transitional phrases "consisting of and
"consisting essentially of shall be closed or semi-closed transitional phrases,
respectively, as set forth in the United States Patent Office Manual of Patent Examining
Procedures, Section 2 111.03.
What is claimed is:
CLAIMS
1. A composition, comprising:
a miniature protein including an alpha helix region, the miniature protein
being modified by substitution of three to six amino acid residues, inclusively,
with arginine residues, the substitutions being at non-sequential positions within
the alpha helix region.
2. The composition of claim 1, wherein the miniature protein, prior to substitution,
is PYY.
3. The composition of claim 1, wherein the miniature protein, prior to substitution,
is avian pancreatic polypeptide.
4. The composition of claim 1, wherein the miniature protein, prior to substitution,
is YY2.
5. The composition of claim 1, wherein the miniature protein is modified by the
substitution of three amino acid residues with arginine residues.
6. The composition of claim 1, wherein the miniature protein is modified by the
substitution of four amino acid residues with arginine residues.
7 . The composition of claim 1, wherein the miniature protein is modified by the
substitution of five amino acid residues with arginine residues.
8. The composition of claim 1, wherein the three to six amino acid substitutions are
each chosen from the group consisting of positions 15, 18, 19, 22, 25, and 26 of
the miniature protein.
9. A composition, comprising:
a miniature protein including a type II polyproline helix region, the
miniature protein being modified by substitution of three to six amino acid
residues, inclusively, with arginine residues, the substitutions being at non¬
sequential positions within the type II polyproline helix region.
10. The composition of claim 9, wherein the miniature protein, prior to substitution,
is PYY.
11. The composition of claim 9, wherein the miniature protein, prior to substitution,
is avian pancreatic polypeptide.
12 The composition of claim 9, wherein the miniature protein, prior to substitution,
is YY2.
13. The composition of claim 9, wherein n is between 3 and 6, inclusively.
14. The composition of claim 9, wherein the miniature protein is modified by the
substitution of three amino acid residues with arginine residues.
15. The composition of claim 9, wherein the miniature protein is modified by the
substitution of four amino acid residues with arginine residues.
16. The composition of claim 9, wherein the miniature protein is modified by the
substitution of five amino acid residues with arginine residues.
17. The composition of claim 9, wherein the miniature protein is modified by the
substitution of six amino acid residues with arginine residues.
18. The composition of claim 9, wherein the type II polyproline helix region is
modified such that the type II polyproline helix region includes at least one
portion having the sequence PPR.
19. The composition of claim 9, wherein the type II polyproline helix region is
modified such that the type II polyproline helix region includes at least one
portion having the sequence (PPR) n, wherein n is at least 3 .
20. A composition, comprising:
a PYY including a type II polyproline helix region, the PYY being
modified by substitution of three to six amino acid residues, inclusively, with
arginine residues.
21. A composition, comprising :
a PYY including a type II polyproline helix region, the PYY being
modified by substitution of at least a portion of the type II polyproline helix
region with the sequence (PPR)n, wherein n is at least 2.
22. A composition, comprising:
APPLPPRN RGEDA SPEEL SRYYR SLP HYLNLVTRQRY (SEQ ID NO:
50).
23. A composition, comprising:
APPLPPRNRGEDASPRELSRYYRSLRHYLNLVTRQRY (SEQ ID NO:
51).
24. A composition, comprising:
APPLPPRNRGEDASPRELRRYYRSLRHYLNLVTRQRY (SEQ ID
NO: 52).
25. A composition, comprising:
a miniature protein including a type II polyproline helix region, the
miniature protein being modified by substitution of at least a portion of the type
II polyproline helix region with the sequence (PPR)n, wherein n is at least 4 .
26. The composition of claim 25, wherein the miniature protein, prior to substitution,
is PYY.
27. The composition of claim 25, wherein the miniature protein, prior to substitution,
is YY2.
28. The composition of claim 25, wherein the miniature protein, prior to substitution,
is avian pancreatic polypeptide.
29. The composition of claim 25, wherein n is between 4 and 6, inclusively.
30. A composition, comprising:
a miniature protein including a type II polyproline helix region, the
miniature protein being modified by substitution of at least a portion of the type
II polyproline helix region with the sequence (PRR)n, wherein n is at least 3 .
31. The composition of claim 30, wherein the miniature protein, prior to substitution,
is PYY.
32. The composition of claim 30, wherein the miniature protein, prior to substitution,
is YY2.
33. The composition of claim 30, wherein the miniature protein, prior to substitution,
is avian pancreatic polypeptide.
34. The composition of claim 30, wherein n is between 3 and 6, inclusively.
35. A composition, comprising:
a miniature protein modified by substitution of at least three amino acid
residues with arginine residues, wherein the substitutions are chosen from the
group consisting of positions 15, 18, 19, 22, 25, and 26 of the avian pancreatic
polypeptide.
36. The composition of claim 35, wherein the miniature protein, prior to substitution,
is PYY.
37. The composition of claim 35, wherein the miniature protein, prior to substitution,
is YY2.
38. The composition of claim 35, wherein the miniature protein, prior to substitution,
is avian pancreatic polypeptide .
39. The composition of claim 35, wherein the miniature protein contains arginine
substitutions in positions 15, 19, 22, and 26.
40. The composition of claim 35, wherein the miniature protein contains arginine
substitutions in positions 15, 19, 22, 25, and 26.
41. The composition of claim 35, wherein the miniature protein contains arginine
substitutions in positions 15, 18, 19, 22, 25, and 26.
42. A composition, comprising:
an avian pancreatic polypeptide (aPP) including an alpha helix region, the
avian pancreatic polypeptide being modified by substitution of three to six amino
acid residues, inclusively, with arginine residues, the substitutions being at non¬
sequential positions within the alpha helix region.
43. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY (SEQ ID NO: 1).
44. The composition of claim 42, wherein the avian pancreatic polypeptide is
modified by substitution of three to six amino acid residues, inclusively.
45. The composition of claim 42, wherein the avian pancreatic polypeptide is
modified by the substitution of three amino acid residues with arginine residues.
46. The composition of claim 42, wherein the avian pancreatic polypeptide is
modified by the substitution of four amino acid residues with arginine residues.
47. The composition of claim 42, wherein the avian pancreatic polypeptide is
modified by the substitution of five amino acid residues with arginine residues.
48. The composition of claim 42, wherein the three to six amino acid substitutions
are each chosen from the group consisting of positions 15, 18, 19, 22, 25, and 26
of the avian pancreatic polypeptide.
49. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFVGRLLAYFGDTINRY (SEQ ID NO: 2) or
GPSQPTYPGDDAPVEDLIRFVGRLLAYFGDTINRYC (SEQ ID NO: 3).
50. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVVDLIRFRGRWL AYLGDTINRY (SEQ ID NO: 4) or
GPSQPTYPGDDAPVVDLIRFRGRWLA YLGDTINRYC (SEQ ID NO: 5).
51. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPLGDLISFRGRFLAYFGDTINRY (SEQ ID NO: 6) or
GPSQPTYPGDDAPLGDLISFRGRFLAYFGDTINRYC (SEQ ID NO: 7).
52. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALTRHRYAAA (SEQ ID NO: 8)
or GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALTRHRYAAAC (SEQ ID
NO: 9).
53. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GKSWMTVPGDDAPVEDLIRFKFLLQWYLLALTRHRYAAA (SEQ ID NO:
10) or GKSWMTVPGDDAPVEDLIRFKFLLQWYLLALTRHRYAAAC (SEQ
ID NO: 11).
54. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALYHNNYAAA (SEQ ID NO:
13) or GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALYHNNYAAAC (SEQ
ID NO: 14).
55. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALSHYNYAAA (SEQ ID NO:
15) or GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALSHYNYAAAC (SEQ
ID NO: 16).
56. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALSLRNYAAA (SEQ ID NO:
17) or GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ ID
NO: 18).
57. The composition of claim 42, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALAADAYAAA (SEQ ID NO:
19) or GPSQPTYPGDDAPVEDLIRFKFLLQWYLLALAADAYAAAC (SEQ
ID NO: 20).
58. A composition, comprising:
an avian pancreatic polypeptide (aPP) including a type II polyproline
helix region, the avian pancreatic polypeptide being modified by substitution of
three to six amino acid residues, inclusively, with arginine residues, the
substitutions being at non-sequential positions within the type II polyproline helix
region.
59. The composition of claim 58, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY (SEQ ID NO: 1).
60. The composition of claim 58, wherein the avian pancreatic polypeptide is
modified by the substitution of three amino acid residues with arginine residues.
6 1. The composition of claim 58, wherein the avian pancreatic polypeptide is
modified by the substitution of four amino acid residues with arginine residues.
62. The composition of claim 58, wherein the avian pancreatic polypeptide is
modified by the substitution of five amino acid residues with arginine residues.
63. The composition of claim 58, wherein the avian pancreatic polypeptide is
modified by the substitution of six amino acid residues with arginine residues.
64. The composition of claim 58, wherein the type II polyproline helix region is
modified such that the type II polyproline helix region includes at least one
portion having the sequence PRR.
65. The composition of claim 58, wherein the type II polyproline helix region is
modified such that the type II polyproline helix region includes at least one
portion having the sequence (PRR)n, wherein n is at least 3 .
66. A composition, comprising:
an avian pancreatic polypeptide (aPP) including a type II polyproline
helix region, the avian pancreatic polypeptide being modified by substitution of
at least a portion of the type II polyproline helix region with the sequence (PPR)n,
wherein n is at least 4.
67. The composition of claim 66, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY (SEQ ID NO: 1).
68. The composition of claim 66, wherein n is between 4 and 6, inclusively.
69. A composition, comprising:
an avian pancreatic polypeptide (aPP) including a type II polyproline
helix region, the avian pancreatic polypeptide being modified by substitution of
at least a portion of the type II polyproline helix region with the sequence (PRR)n,
wherein n is at least 3.
70. The composition of claim 69, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY (SEQ ID NO: 1).
71. The composition of claim 69, wherein n is between 3 and 6, inclusively.
72. A composition, comprising:
an avian pancreatic polypeptide modified by substitution of at least three
amino acid residues with arginine residues, wherein the substitutions are chosen
from the group consisting of positions 15, 18, 19, 22, 25, and 26 of the avian
pancreatic polypeptide.
73. The composition of claim 72, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY (SEQ ID NO: 1).
74. The composition of claim 72, wherein the avian pancreatic polypeptide contains
arginine substitutions in positions 15, 19, 22, and 26.
75. The composition of claim 72, wherein the avian pancreatic polypeptide contains
arginine substitutions in positions 15, 19, 22, 25, and 26.
76. The composition of claim 72, wherein the avian pancreatic polypeptide contains
arginine substitutions in positions 15, 18, 19, 22, 25, and 26.
77. A composition, comprising:
GPSQPTYPGDDAPVRDLRRFYRDLRRYLNVVTRHRY (SEQ ID NO:
21).
78. A composition, comprising:
GPSQPTYPGDDAPVRDLIRFYRDLRRYLNVVTRHRY (SEQ ID NO:
22).
79. A composition, comprising:
GPSQPTYPGDDAPVRDLIRFYRDLQRYLNVVTRHRY (SEQ ID NO:
23).
80. A composition, comprising:
an avian pancreatic polypeptide (aPP) including an alpha helix region that
is substantially cationic.
81. A composition, comprising:
an avian pancreatic polypeptide (aPP) including a type II polyproline
helix region that is substantially cationic.
82. A composition, comprising:
a cell-permeable avian pancreatic polypeptide.
83. A composition, comprising:
a modified avian pancreatic polypeptide that, when exposed to HeLa cells
at a concentration of 1 micromolar, equilibrates inside the HeLa cells at a
concentration that is at least 75 times greater than the equilibration concentration
of an unmodified avian pancreatic polypeptide exposed to the HeLa cells under
the same conditions.
84. The composition of claim 83, wherein the concentration of the modified avian
pancreatic polypeptide inside the HeLa cells is at least 100 times greater than the
concentration of the unmodified avian pancreatic polypeptide inside the HeLa
cells under the same conditions.
85. A composition, comprising:
a protein selected from the group consisting of










ID NO: 29), and
GPPRPPRPPRPPRPPRPPRGDDAPVEDLIRFYNDLQQYLNVVTRHRYC
(SEQ ID NO: 30).
86. A composition, comprising:
a miniature protein that is cell permeable and able to bind to Bcl2 with a
Kd of at least about 7 nM.
87. The composition of claim 86, wherein Kd is at least about 50 nM.
88. The composition of claim 86, wherein the miniature protein is an avian pancreatic
polypeptide.
89. The composition of claim 86, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY (SEQ ID NO: 1).
90. A composition, comprising:
a miniature protein that is cell permeable and able to bind to hDM2 with a
Kd of at least about 10 nM.
91. The composition of claim 90, wherein the miniature protein is an avian pancreatic
polypeptide.
92. The composition of claim 91, wherein the avian pancreatic polypeptide has a
sequence, before modification, of
GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRY (SEQ ID NO: 1).
93. The composition of claim 90, wherein the miniature protein is cell permeable and
able to bind to hDM2 with a Kd of at least about 30 nM.
94. The composition of claim 90, wherein the miniature protein is cell permeable and
able to bind to hDM2 with a Kd of at least about 100 nM.
95. The composition of claim 90, wherein the miniature protein is cell permeable and
able to bind to hDM2 with a Kd of at least about 300 nM.
96. A composition, comprising:
GPRRPRRPGRRAPVEDLIRFVGRLLA YFGDT ΓNRYC (SEQ ID NO:
31).
97. A composition, comprising:
GPRRPRRPGRRAPVVDLIRFRGRWL AYLGDTΓNRYC (SEQ ID NO:
32).
98. A composition, comprising:
GPRRPRRPGRRAPLGDLISFRGRFLA YFGDTINRYC (SEQ ID NO:
33).
99. A composition, comprising:
G(PRR) nPGRRAPVEDLIRFVGRLLAYFGDTINRYC (SEQ ID NO: 40),
wherein n is at least 2.
100. A composition, comprising:
G(PRR) nPGRRAPVVDLIRFRGRWLAYLGDTINRYC (SEQ ID NO:
41), wherein n is at least 2.
101. A composition, comprising :
G(PRR) nPGRRAPLGDLISFRGRFLAYFGDTINRYC (SEQ ID NO: 42),
wherein n is at least 2.
102. A composition, comprising:
GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ
ID NO: 34).
103. A composition, comprising:
GPRQPRYPGRDAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ
ID NO: 35).
104. A composition, comprising:
GPSRPTRPGDRAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ
ID NO: 36).
105. A composition, comprising:
GPRRPRRPGRRAPVEDLIRFKFLLQWFLLALTRHRYAAAC (SEQ
ID NO: 37).
106. A composition, comprising:
GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALYHNNYAAAC (SEQ
ID NO: 38).
107. A composition, comprising:
GPRRPRRPGRRAPVEDLIRFKFLLQWYLLALSHYNYAAAC (SEQ
ID NO: 39).
108. A composition, comprising:
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALSLRNYAAAC (SEQ ID
NO: 43), wherein n is at least 2.
109. A composition, comprising:
G(PRR)nPGRRAPVEDLIRFKFLLQWFLLALTRHRYAAAC (SEQ ID
NO: 44), wherein n is at least 2.
110. A composition, comprising:
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALYHNNYAAAC (SEQ ID
NO: 45), wherein n is at least 2.
111. A composition, comprising:
G(PRR)nPGRRAPVEDLIRFKFLLQWYLLALSHYNYAAAC (SEQ ID
NO: 46), wherein n is at least 2.
112. A composition, comprising:
a miniature protein that, when exposed to a population of Jurkat cells at a
concentration of 10 micromolar, induces apoptosis in at least about 50% of the
Jurkat cells.
113. A composition, comprising :
an avian pancreatic polypeptide (aPP) including a type II polyproline
helix region, the avian pancreatic polypeptide being modified by substitution of
three to six amino acid residues, inclusively, with arginine residues.
114. A composition, comprising:
an avian pancreatic polypeptide (aPP) including an alpha helix region, the
avian pancreatic polypeptide being modified by substitution of three to six amino
acid residues, inclusively, with arginine residues.
115. A composition, comprising:
an avian pancreatic polypeptide (aPP) including a type II polyproline
helix region, the avian pancreatic polypeptide being modified by substitution of
at least a portion of the type II polyproline helix region with the sequence (PPR) n,
wherein n is at least 2.
116. A composition, comprising:
RRPRRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ
ID NO: 47).
117. A composition, comprising:
RRPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ ID
NO: 48).
118. A composition, comprising:
GPRRPRRPGRRAPVEDLIRFYNDLQQYLNVVTRHRYC (SEQ ID
NO: 49).
119. A composition, comprising:
a cell-permeable miniature protein.
120. A composition, comprising:
a miniature protein including an alpha helix region that is substantially
cationic.
121. A composition, comprising:
a miniature protein including a type II polyproline helix region that is
substantially cationic.
122. A composition, comprising:
a modified miniature protein that, when exposed to HeLa cells at a
concentration of 1 micromolar, equilibrates inside the HeLa cells at a
concentration that is at least 75 times greater than the equilibration concentration
of an unmodified miniature protein exposed to the HeLa cells under the same
conditions.
123. A composition, comprising:
a protein modified by the addition of (PRR)n, wherein n is at least 2,
wherein the protein, after modification, equilibrates inside HeLa cells at a
concentration that is at least 75 times greater than the equilibration concentration
of an unmodified protein exposed to the HeLa cells under the same conditions.
124. A composition, comprising:
a protein modified by the addition of (PPR)n, wherein n is at least 2,
wherein the protein, after modification, equilibrates inside HeLa cells at a
concentration that is at least 75 times greater than the equilibration concentration
of an unmodified protein exposed to the HeLa cells under the same conditions.
125. A composition, comprising:
a protein containing the sequence (PPR)n, wherein n is at least 2.
126. The composition of claim 125, wherein n is at least 3.
127. A composition, comprising:
a protein containing the sequence (PRR)n, wherein n is at least 2.
128. The composition of claim 127, wherein n is at least 3 .








